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Abstract 
 
Inflammation, in general, is a physiological response of the body to different types of tissue 
injury, causing a cascade of coordinated cellular and biochemical reactions. Neurodegenerative, 
inflammatory and neoplastic disorders involve neuroinflammatory reactions that isolate the 
damaged tissue and promote immune responses. Likewise, neuroinflammation (NI) implicates a 
complex orchestrated response to various stimuli in the central nervous system (CNS) aiming 
towards tissue preservation and restoration. Neuroinflammatory reactions involve a cellular 
response by activating cells of the monocyte lineage, whether resident or circulating. Microglia are 
the resident cells of the monocyte lineage in the CNS and their activation constitutes a main 
feature of neuroinflammation. The process involves an overexpression of the 18 kDa 
translocator protein (TSPO) receptor by cells of monocyte/macrophage lineage and, in the 
central nervous system (CNS), by activated microglia. PK11195 is a specific ligand for the TSPO 
receptor and therefore a marker for activated microglia. The (R)-enantiomer radiolabelled with 
Carbon-11, (R)-[N-Methyl-11C]PK11195, is the most widely used radiotracer for in vivo TSPO 
imaging with PET.  
In this work we report on the optimisation of the synthesis, purification and reformulation 
of (R)-[N-methyl-11C]PK11195 by the captive solvent method with the aim of being used for in 
vivo PET imaging studies. 
Carbon-11 is obtained as [11C]CO2 by irradiation of a gas target (N2+0.5% O2) using the 
14N(p,α)11C nuclear reaction in a IBA Cyclone 18/9 cyclotron. [11C]CH3I is produced by the 
‘liquid-phase’ reduction of [11C]CO2 with LiAlH4/THF(0.1M) to [
11C]CH3OLi and further 
addition of HI on a methyl iodide production system. [11C]CH3I is then distilled at 120 ºC, 
trapped in captive solvent loop pre-loaded with (R)-[N-desmethyl]PK11195 precursor solution 
(dissolved on 100 μl of DMSO and saturated with 30 mg of KOH), and reaction takes place. 
Reaction products ([11C]-X) go through a semi-preparative reverse-phase C18 HPLC column for 
purification. Finally, (R)-[N-methyl-11C]PK11195 is formulated in 9 ml of physiological saline (0.9 
%) and 1 ml of EtOH, and filtered through a sterilizing 0.22 μm membrane filter. 
Synthesis process is carried out in about 35 minutes, and quality control tests were 
performed to ensure the good quality of product. 149.71±50.25 mCi of (R)-[11C]PK11195 were 
obtained at EOS with specific activities between 15-25 GBq/μmol on a short overall synthesis 
time. 
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The captive solvent method offers an easy and reproducible way to automate the routine 
production of [11C]-labelled radiopharmaceuticals for human use. The production method is fast, 
considering the short half-life of carbon-11 (20.4 min.) and can produce the final products in 
high radiochemical purities and good specific activities. 
 
Keywords: [11C]PK11195, carbon-11, captive solvent loop, ‘wet’ method, [11C]CO2, 
[11C]CH3I, neuroinflammation, microglia, TSPO, PET. 
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Resumo 
 
A inflamação, em geral, é uma resposta fisiológica do corpo para com diferentes tipos de 
lesão do tecido, provocando uma cascata coordenada de reacções celulares e bioquímicas. 
Distúrbios neurodegenerativos, inflamatórios e neoplásicos envolvem reacções 
neuroinflamatórias que isolam o tecido danificado e promovem respostas imunitárias. Da mesma 
forma, a neuroinflamação (NI) implica uma complexa e orquestrada resposta a vários estímulos 
no sistema nervoso central (SNC), com vista para a preservação do tecido e sua restauração. 
Reacções neuroinflamatórias envolvem uma resposta celular através da activação de células da 
linhagem do monócito, residentes ou circulantes. Microglia são as células residentes da linhagem 
dos monócitos no SNC e a sua activação, constitui uma característica principal da 
neuroinflamação. O processo envolve uma sobre expressão dos receptores da proteína 
translocadora de 18 kDa (TSPO) em células da linhagem dos monócitos/macrófagos e, no 
sistema nervoso central (SNC), pela activação da microglia. PK11195 é um ligando selectivo para 
o receptor da TSPO e, portanto, um identificador da microglia activada. O enantiómero (R) 
marcado radioactivamente com carbono-11, (R)-[N-metil-11C]PK11195, é o radiotraçador mais 
utilizado para imagiologia in vivo da TSPO com PET. 
Neste trabalho, reportamos a optimização da síntese, purificação e reformulação de 
(R)-[N-metil-11C] PK11195 pelo ‘captive solvente method’ com a finalidade de ser utilizado para 
imagem in vivo em estudos de PET. 
Carbono-11 é obtido sob a forma de [11C]CO2 por irradiação de um alvo de gás 
(N2+O2 0,5%), utilizando a reacção nuclear 
14N(p,α)11C num ciclotrão. [11C]CH3I é produzido por 
redução de [11C]CO2 com LiAlH4/THF (0,1 M) via ‘fase liquida’ a [
11C]CH3OLi, e pela adição 
posterior de HI em um sistema de produção de iodeto de metilo, o [11C]CH3I é destilado a 120ºC. 
Ao mesmo tempo, o [11C]CH3I destilado é aprisionado num loop previamente carregado com 
uma solução da molécula precursora desmetilada (R)-[N-desmetil]PK11195 (dissolvida em 100μl 
de DMSO e saturada com 30mg de KOH), iniciando-se a reacção ao mesmo tempo que se 
aprisiona o [11C]CH3I. Produtos da reacção ([11C]-X) passam por uma coluna HPLC semi-
preparativa de fase reversa (C18) para purificação. Finalmente, (R)-[N-metil-11C]PK11195 foi 
formulado em 9ml de soro fisiológico (0,9%) e 1ml de EtOH e filtrado através de um filtro 
esterilizado de membrana de 0,22μm. 
O processo de síntese realiza-se em cerca de 35 minutos, e testes de controlo de qualidade 
foram realizados para garantir a boa qualidade do produto. 149,71±50,25mCi de 
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(R)-[11C]PK11195 foram obtidos no final da síntese com actividades específicas entre 
15-25GBq/μmol num curto período de síntese. 
O ‘captive solvente loop’ proporciona uma maneira fácil e reprodutível para automatizar a 
produção de rotina de radiofármacos marcados com 11C para uso humano. O método de 
produção é rápida, tendo em conta a curta meia-vida do carbono-11 (20,4 min), podendo-se 
produzir produtos finais com elevada pureza radioquímica e boa actividade específica. 
 
Palavras Chave: [11C]PK11195, carbono-11, captive solvent loop, ‘wet’ method, [11C]CO2, 
[11C]CH3I, neuroinflamação, microglia, TSPO, PET. 
 
 
vii 
 
Index 
 
Acknowledgments ................................................................................................................................................................ i 
Abstract ............................................................................................................................................................................ iii 
Resumo .............................................................................................................................................................................. v 
Index ............................................................................................................................................................................... vii 
List of Figures ................................................................................................................................................................... xi 
List of Tables .................................................................................................................................................................. xiii 
Acronyms ......................................................................................................................................................................... xv 
 
CHAPTER 1 
Introduction ................................................................................................................................................................... 1 
Part I: General Introduction ........................................................................................................................................ 1 
1.1. Objectives ............................................................................................................................................................ 2 
1.1.1. Timeline of the Project .............................................................................................................................. 3 
1.2. The Institute for Nuclear Sciences Applied to Health ................................................................................. 3 
Part II: Theoretical Background.................................................................................................................................. 5 
1.3. Neuroinflammation ........................................................................................................................................... 5 
1.4. Microglia .............................................................................................................................................................. 5 
1.4.1. Activated stage of microglia ...................................................................................................................... 6 
1.5. 18 kDa Translocator Protein ............................................................................................................................ 7 
1.5.1. Structure ....................................................................................................................................................... 7 
1.5.2. Function ....................................................................................................................................................... 8 
1.5.3. TSPO in neuroinflammation .................................................................................................................... 9 
1.5.4. TSPO ligands.............................................................................................................................................10 
1.6. (R)-[11C]PK11195 .............................................................................................................................................12 
1.6.1. PET imaging studies of TSPO in human diseases ..............................................................................14 
1.6.2. PK11195 limitations .................................................................................................................................18 
1.7. Molecular Imaging ...........................................................................................................................................18 
1.7.1. Molecular imaging probe concept ..........................................................................................................19 
1.7.2. Principles of Positron Emission Tomography ....................................................................................20 
1.8. Radiochemistry .................................................................................................................................................26 
1.8.1. Carbon-11 ..................................................................................................................................................27 
1.8.2. Production of 11C .....................................................................................................................................28 
1.9. Half-life of the radionuclide ...........................................................................................................................29 
 
viii 
 
CHAPTER 2 
Materials and Methods ............................................................................................................................................... 33 
2.1. Background ....................................................................................................................................................... 33 
2.1.1. The captive solvent loop ......................................................................................................................... 34 
2.1.2. Quality control of PET radiolabelled compounds .............................................................................. 35 
2.2. Aims ................................................................................................................................................................... 35 
2.3. Automation of radiosynthesis for (R)-[N-methyl-11C]PK11195 .............................................................. 36 
2.3.1. General ....................................................................................................................................................... 36 
2.3.2. Automated synthesis module ................................................................................................................. 37 
2.3.3. Production of [11C]CO2 ........................................................................................................................... 41 
2.3.4. Production of [11C]CH3I ......................................................................................................................... 42 
2.3.5. Radiosynthesis of (R)-[N-methyl-11C]PK11195 .................................................................................. 43 
2.3.6. Product reformulation ............................................................................................................................. 44 
2.3.7. Quality control .......................................................................................................................................... 45 
 
CHAPTER 3 
Results ........................................................................................................................................................................... 47 
3.1. Production of [11C]methyl iodide: initial optimisations ............................................................................. 48 
3.1.1. Specific activity optimisation .................................................................................................................. 49 
3.2. Captive solvent loop methylation: initial optimisations............................................................................. 53 
3.2.1. Solvents and bases chosen ...................................................................................................................... 53 
3.2.2. Precursor concentration: influence on RCY ........................................................................................ 54 
3.2.3. Reaction time ............................................................................................................................................ 55 
3.3. Purification and formulation of (R)-[11C]PK11195 .................................................................................... 56 
3.4. Routine radiolabelling of (R)-[N-methyl-11C]PK11195 ............................................................................. 58 
 
CHAPTER 4 
Discussion .................................................................................................................................................................... 61 
4.1. Automation of [11C]methyl iodide production ............................................................................................ 62 
4.1.1. Specific Activity ........................................................................................................................................ 62 
4.1.2. Synthesis module: routine maintenance ................................................................................................ 64 
4.2. Radiolabelling (R)-[11C]PK11195 on a captive solvent loop ..................................................................... 65 
4.2.1. Initial optimisation ................................................................................................................................... 65 
4.2.2. Purification and reformulation of (R)-[11C]PK11195 ......................................................................... 66 
4.3. Routine synthesis, purification and reformulation of (R)-[N-methyl-11C]PK11195 ............................. 66 
 
 
ix 
 
CHAPTER 5 
Conclusion ....................................................................................................................................................................69 
 
CHAPTER 6 
Future perspectives .....................................................................................................................................................71 
 
REFERENCES .........................................................................................................................................................73 
 
 
xi 
 
List of Figures 
 
Figure 1.1 Timeline of the work during the final year project. .............................................................................................. 3 
Figure 1.2 Structures of TSPO as a hetero-oligomeric complex.. ......................................................................................... 8 
Figure 1.3 Schematic diagram of the hetero-oligomeric complex localized on the outer mitochondrial 
membrane of astrocytes and microglia.. .................................................................................................................. 8 
Figure 1.4 Schematic diagram of function and mechanism of 18 kDa translocator protein (TSPO). ..........................10 
Figure 1.5 Chemical structures of some TSPO-selective compounds ................................................................................11 
Figure 1.6 Chemical structures of isoquinoline carboxamides. ............................................................................................12 
Figure 1.7 Chemical structures of (R)- and (S)-[11C]PK11195. ............................................................................................13 
Figure 1.8 PET scans with [11C]PK11195 of a healthy subject and a Parkinson’s disease patient. Mild 
microglial activation is seen in the thalamus of the healthy control but a significantly raised 
activation is evident in the midbrain and striata of the PD patient. .................................................................15 
Figure 1.9 Increased [11C]PK11195 binding potential (BPND) in a Multiple Sclerosis patient when compared 
to a healthy normal control. ....................................................................................................................................16 
Figure 1.10 Significant increase of (R)-[11C] PK11195 uptake in Alzheimer’s Disease patients when compared 
with control ................................................................................................................................................................17 
Figure 1.11 Several key criteria for probes in molecular imaging. Adapted from [58]. ......................................................19 
Figure 1.12 Principle of PET detection. .....................................................................................................................................22 
Figure 1.13 General views of two cyclotrons from different eras First Livingston cyclotron in 1931 and an 
IBA Cyclone 18/9 cyclotron. ..................................................................................................................................23 
Figure 1.14 Schematic structure of cyclotron showing the ‘dee’ structure, the ion source and the magnet.. ................23 
Figure 1.15 Schematic top view of the main body of an IBA Cyclone 18/9 cyclotron.....................................................25 
Figure 1.16 Pathways to produce 11C-labelling precursors. ....................................................................................................28 
 
Figure 2.1 Apparatus and flow diagram for trapping [11C]methyl iodide on HPLC loop, pre-charged 
(coated) with a non-radioactive precursor. The labelling reaction takes place instantly before 
injection into an HPLC semi-preparative column for purification ..................................................................34 
Figure 2.2 Schematic diagram of the [11C]methyl iodide production system ....................................................................38 
Figure 2.3 Schematic diagram of the [11C]methylation system. ............................................................................................39 
Figure 2.4 Schematic diagram of the disposable reformulation kit for product formulation used on 
reformulation system. ...............................................................................................................................................40 
xii 
 
Figure 2.5 Reaction scheme for the synthesis of [11C]methyl iodide.................................................................................. 42 
Figure 2.6 Reaction scheme for the convertion of [11C]methyl iodide into [11C]methyl triflate. .................................. 43 
Figure 2.7 Reaction scheme of the of the (R)-[11C]PK11195 synthesis in a captive solvent loop system. .................. 44 
Figure 2.8 Analytical UV HPLC trace for co-injection of (R)-[N-methyl-12C]PK11195 standard solution and 
(R)-[N-desmethyl]PK11195 precursor solution. .................................................................................................. 46 
 
Figure 3.1 Radiosynthesis progress of (R)-[N-methyl-11C]PK11195 from EOB to EOS. ............................................. 47 
Figure 3.2 Diagram of in-process controls during [11C]CH3I production.. ...................................................................... 48 
Figure 3.3 Amount of ‘cold’ CH3I formed without pre-conditioning of molecular sieves before synthesis 
and with pre-conditioning just before the synthesis. ......................................................................................... 49 
Figure 3.4 Amount of ‘cold’ CH3I formed without filtration of inert gas supplier of methyl iodide system 
and with filtration. .................................................................................................................................................... 50 
Figure 3.5 Amount of [12C]CH3I generated under scenarios Sc1, Sc2 and Sc3 described above (A). The 
influence of [12C]CO2 source by LiAlH4 (Sc1), release of CO2 from MS (Sc2) and the load-
unload of the target (Sc3) was shown on graph of the right (B). ..................................................................... 51 
Figure 3.6 Effect of the bombarding time on the final amount of [12C]CH3I ................................................................. 52 
Figure 3.7 Influence of precursor solvent (MEK, DMSO and DMF) on the trapping efficacy of [11C]CH3I 
and [11C]CH3OTf on the captive solvent loop.................................................................................................... 53 
Figure 3.8 Influence of precursor ((R)-[N-desmethyl]PK11195) concentration in radiochemical yield and in 
the ratio [11C]PK11195/[11C]CH3I and total amount of radioactivity of both at EOS affected by 
precursor concentration. ......................................................................................................................................... 55 
Figure 3.9 Effect of reaction time in [11C]PK11195 production. Radiochemical yields and total activity of 
[11C]PK11195 at the end of synthesis. .................................................................................................................. 55 
Figure 3.10 Semi-preparative HPLC separation of (R)-[N-methyl-11C]PK11195. ............................................................. 56 
Figure 3.11 Formulation of [11C]PK11195 by solid phase extraction on the reformulation system. ............................. 56 
Figure 3.12 Filtration testes of (R)-PK11195 with 0.22µm sterile filters using a solution of saline at 10% of 
ethanol. ....................................................................................................................................................................... 57 
Figure 3.13 Analytical HPLC traces for a final (R)-[N-methyl-11C]PK11195 product sample ........................................ 59 
 
 
xiii 
 
List of Tables 
 
Table 1.1 Physical Proprieties of the most common short lived positron-emitting isotopes: 
Carbon-11 (11C), Fluoride-18 (18F), Nitrogen-13 (13N) and Oxygen-15 (15O). *EC: 
Electron capture. ..................................................................................................................................... 20 
Table 1.2 Characteristics of carbon-11 as a PET isotope. ................................................................................. 27 
Table 1.3 Nuclear reactions used to produce carbon-11. Natural abundance of the irradiated 
stable isotope is listed in the last column. ........................................................................................... 29 
 
Table 2.1 Steps for production of [11C]CH3I from [11C]CO2 by the ‘wet method’. ....................................... 42 
 
Table 3.1 Production conditions for [11C]CH3I. .................................................................................................. 48 
Table 3.2 Summary of the results of influence of different solvents and bases in the synthesis of 
(R)-[N-methyl-11C]PK11195. ................................................................................................................. 54 
Table 3.3 Influence of precursor concentration in the synthesis of [11C]PK11195. ...................................... 54 
 
 
 
xv 
 
Acronyms 
 
[11C]CH3I [11C]Methyl Iodide 
[11C]CH3OTf [11C]Methyl Triflate 
[11C]CH4 [11C]Methane 
[11C]CO2 [11C]Carbon dioxide 
[11C]PK11195 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide labelled 
with carbon-11 
µA micro-Ampere 
11B Boron-11 
11C Carbon-11 
12C Carbon-12 
13N Nitrogen-13 
14N Nitrogen-14 
15O Oxygen-15 
18F Fluorine-18 
3D Three-dimensional 
AD Alzheimer’s disease 
AgOTf Silver Trifluoromethanesulfonate (or Silver Triflate) 
Ah Ampere-hour 
ANT Adenine Nucleotide Transporter 
ATP Adenosine-5'-triphosphate 
BBB Blood Brain Barrier 
Bq Bequerel 
Ci Curie 
CNS Central Nervous System 
CT Computed Tomography 
DC Decay Corrected 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
e.g. exempli gratia ("for example") 
EC Electron Capture 
EOB End Of Bombardment 
EOS End Of Synthesis 
EtOH Ethanol 
eV eletron Volt 
xvi 
 
FDG 2-[18F]-fluoro-2-deoxy-D-glucose 
FPV Final Product Vial 
GABA γ-aminobutyric acid 
GC Gas Chromatography 
GMP Good Manufacturing Practice 
H2 Hydrogen 
H2O Water 
HCl Hydrochloric Acid 
HD Huntington’s disease 
He Hellium 
HI Hydriodic Acid 
HIV Human Immunodeficiency Virus 
HPLC High Performance Liquid Chromatography 
i.e. id est (“that is”) 
ICNAS Institute for Nuclear Sciences Applied to Health (Instituto de Ciências Nucleares 
Aplicadas à Saúde) 
IUPAC International Union of Pure and Applied Chemistry 
kDa kiloDalton 
KOH Potassium Hydroxide 
LiAlH4 Lithium Aluminium Hydride 
MEK Methyl Ethyl Ketone 
MI Molecular Imaging 
MI Molecular ImagingMS Multiple Sclerosis 
min Minutes 
mol mole 
MRI Magnetic Resonance Imaging 
MS Molecular Sieves 
N2 Nitrogen 
NaCl Sodium Chloride 
NaF Sodium [18F]fluoride 
NDC Non-Decay Corrected 
NI Neuroinflammation 
ºC Degree Celsius 
P2O5 Phosphorus Pentoxide 
PBR Peripheral Benzodiazepine Receptor 
PD Parkinson’s disease 
PET Positron Emission Tomography 
PiB Pittsburgh Compound B 
xvii 
 
PK11195 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide 
PVDF Polyvinylidene Difluoride 
QC Quality Control 
R&D Research and Development 
RCY Radiochemical Yield 
SA Specific Activity 
SPE Solid Phase Extraction 
SPECT Single Photon Emission Computed Tomography 
TBAOH Tetrabutylammonium Hydroxide 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
TOI Time Of Injection 
TSPO Translocator Protein (18kDa) 
UC University of Coimbra 
US Ultrasound 
UV Ultraviolet 
v/v Volume to Volume 
VDAC Voltage-Dependent Anion Channel 
β+ Positron 
 
1 
 
 
Introduction 
 
PART I: General Introduction 
Inflammation, in general, is a physiological response of the body to different types of tissue 
injury, causing a cascade of coordinated cellular and chemical reactions. The inflammatory 
process isolates the damaged tissue and promotes an immune response [1]. Likewise, 
neuroinflammation (NI) implicates a complex orchestrated response to various stimuli in the 
central nervous system (CNS) aiming toward tissue preservation and restoration. 
Neuroinflammatory reactions involve a cellular response by activating cells of the monocyte 
lineage, whether resident or circulating. Microglia are the resident cells of the monocyte lineage in 
the CNS and their activation constitutes a main feature of neuroinflammation [2].  
This activated stage of microglia, upregulates the expression of the 18 kDa translocator 
protein (TSPO), which can be detected in vivo by positron emission tomography (PET) imaging 
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using a selective TSPO radioligand [3]. One of the first PET ligands for human studies of 
activated microglia (TSPO overexpression) was PK11195, a lipid soluble isoquinoline 
carboxamide, labelled with carbon-11 ([11C]PK11195) [4], and it still today the most widely used 
radiotracer for in vivo TSPO imaging [5]. In this work we report on the optimisation of the 
synthesis, purification and reformulation of (R)-[N-methyl-11C]PK11195 with the aim of being 
used for in vivo PET imaging studies. 
 
1.1. Objectives 
The aim of this work is to optimize and automate the synthesis, purification and 
reformulation of (R)-[N-methyl-11C]PK11195 in order to produce a stable, sterile and 
ready-to-inject solution of the radiopharmaceutical with sufficient activity and quality to be used 
in clinical PET studies of neuroinflammation. A substantial part of the work developed is 
applicable to other carbon-11 (11C) labelled compounds and, in fact, has been of critical 
importance for the production of other tracers, notably [11C]Pittsburg Compound B  ([11C]PiB). 
Accordingly, the main objectives of the work are: 
- Optimisation of synthesis process: reagents, reaction times, temperatures, solvents 
and bases; 
- Reformulation of product in a ready-to-inject solution; 
- Quality assurance of the product, e.g., quality control; 
- Quality control of the product: radiochemical yield, specific activity, chemical and 
radiochemical purity, residual organic solvents, apyrogenecity and sterility; 
- Programming and automation of the modules for routine production and 
troubleshooting; 
- Cost optimisation of all components required for the production process 
(disposable spare parts, valves, reagents and solvents). 
This was done in parallel with normal activities of a busy radiochemistry laboratory, 
including active participation in routine as well as clinical and pre-clinical production tasks. 
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1.1.1. Timeline of the Project 
 
 
Writing final 
MSc thesis 
Formulation and quality 
optimisation of product 
Synthesis process 
optimisation 
Programming module 
for adaptation of  
existing scripts 
Non-Curricular 
Traineeship 
SEPTEMBER 
2012 
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Integration 
in team 
Know and master 
the equipment  
Adaptation of 
existent scripts 
Troubleshoot of 
hardware problems 
[11C]CH3I production 
optimisation 
Captive solvente loop 
[11C]methylation optimisation 
Specific activity optimisation 
[11C]PK11195 
formulation 
Purification of [11C]PK11195 
optimisation 
 
 
Figure 1.1 Timeline of the work during the final year project. 
 
Involvement in all laboratory activities included a substantial contribution for an optimized 
production of [11C]PiB ([11C]Pittsburg Compound B). This radioligand is a benzothiazole 
derivative of thioflavin T that is used to image beta-amyloid deposits in Alzheimer’s disease 
patients with positron emission tomography (PET).  
This collaboration work was also presented on the 2nd Bioengineering Meeting IEEE-
EMBS: 
G. Clemente, V. Alves, A.J. Abrunhosa, “Synthesis Optimisation of Pittsburgh Compound B by the 
Captive Solvent Method” – Acceptance for oral presentation at the 2nd Bioengineering Meeting IEEE-
EMBS (February, 2012 in Coimbra, Portugal). 
 
1.2. The Institute for Nuclear Sciences Applied to Health 
The work was developed at Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), 
more exactly at the Radiochemistry and Cyclotron laboratory managed by ICNAS-Produção, 
Unipessoal, Lda. 
ICNAS is an organic unit of University of Coimbra (UC) sited on the Health Campus, and 
is devoted to basic as well as clinical research on the biomedical use of radiation. It was opened in 
2009 and since then the radiochemistry laboratory has made available several 
radiopharmaceuticals labelled with short-live positron emitters (fluorine-18 and carbon-11) for 
research as well as routine clinical studies. Besides [18F]FDG, ICNAS is currently producing other 
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18F-based molecules such as [18F]NaF and [18F]Fluorocholine. As for carbon-11, the list of 
molecules available include [11C]PiB, [11C]PK11195, [11C]Raclopride and [11C]Flumazenil. 
ICNAS is equipped with a full GMP licensed laboratory for the production of 
radiopharmaceuticals and since December 2011 holds a Marketing Authorization for its own 
[18F]FDG. 
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Part II: Theoretical Background 
1.3. Neuroinflammation 
The inflammatory process [2], as a physiological response to tissue insults, is basically a 
complex orchestrated chemical and cellular response to various stimuli aiming toward tissue 
preservation and restoration. The inflammatory reaction isolates the damaged tissue and 
promotes immune responses, leading to a local production of cytokines: protein molecules that 
are responsible for the mechanisms of cellular differentiation. This culminates in the formation of 
a scar which isolates physically the lesion form healthy tissue, which is generally beneficial in 
neutralizing potential threats by minimizing cellular damage and contributing to support repair 
and regeneration (acute inflammation). On the other hand, when excessive or persistent 
inflammation degenerates the tissue injury, the inflammatory response can be detrimental, 
initiating cellular damage (chronic inflammation). The central nervous system (CNS) is 
characterised by a limited ability to regenerate its own tissues, thus chronic neuroinflammation is 
closely related with several neurodegenerative disorders such as Parkinson’s disease (PD), 
Huntington’s disease (HD), Dementias and Multiple sclerosis [3]. Acute neuroinflammation is 
generally caused by some neuronal injury after which microglia migrates to the injured site to 
minimize injury and promotes tissue repair. Otherwise, in chronic neuroinflammation, microglia 
remains activated for an extended period of time and the production of mediators is continuous. 
This response of microglial cells contributes to an increase of the neurodestructive effects, and 
the worsening of the disease [6]. In fact, there is no longer a clear distinction between acute and 
chronic states of inflammation, and in the CNS, the distinction has not been applied consistently 
prevailing the notion that when inflammation is present , chronic neuroinflammation is presumed 
[6]. 
 
1.4. Microglia 
Microglia cells are critical in the protection of the brain parenchyma against brain injuries 
such as infection, trauma, ischemia, brain tumours and neurodegenerative diseases. These cells 
are the resident macrophages of the central nervous system and they are the main component of 
immune defence on the CNS, since they have the ability to become phagocytes, when needed [3]. 
They make up approximately 20% of the total glial population of the CNS, and act as a first line 
of defence against pathological insults at this primary site [7, 8]. Del Rio Hortega was the first to 
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recognize the pathological importance of microglia in CNS, and he also coined the term [9]. In a 
healthy brain parenchyma, resting microglia do not engage in phagocytic or pinocytic activity. 
After an injury or CNS disease, microglial cells abandon their ramified resting-like morphology 
and become activated, acquiring phagocytic properties and respond to tissue insult with a 
complex array of inflammatory cytokines and actions, essentials for the annihilation of the 
neuronal insult [3, 10]. Derived from the monocytic lineage, these cells display high sensitivity to 
different types of CNS injury [11], and they are able to respond quickly. 
 
1.4.1. Activated stage of microglia 
Microglia activation plays an important role in neuroinflammation. During the process, 
cells change from a resting phenotype to an activated phenotype in response to a wide variety of 
CNS insults. That does not mean that microglial cells are totally inactive during resting state. 
Quite the contrary, cells are actually quite active, and regulate their processes by continuously 
monitoring the external milieu [12, 13]. 
During neuroinflammation, the microglia cells suffer drastic changes in their morphology, 
migrate to the lesion site, proliferate and produce neurotoxic factors such as proinflammatory 
cytokines and reactive oxygen species. This morphological change is an important characteristic 
that can be observed after activation. Cells undergo changes from a ramified structure to a hyper-
ramified and at last to an amoeboid morphology that is fully capable of fagocytosis. The 
amoeboid structure facilitates migration of the microglial cell through the parenchyma to the 
lesion sites to engulf the offending material. Microglia can become activated by disruption of the 
blood brain barrier (BBB), fluxes in extracellular glutamate, extracellular ATP from damage cells, 
and disrupted tonic inhibition via fractalkine receptor [14]. 
Most immune receptors that are essential to the initiation and propagation of immune 
responses are constitutively expressed at low levels on microglia. The immunologically relevant 
molecules are upregulated during the microglial activation, and the production of inflammatory 
mediators is stimulated [15]. Several phagocytic receptors are also expressed by microglia, 
functioning as the “professional” phagocytes of the CNS.  
Microglia is actively repressed through signals coming from electrically active neurons, and 
when this tonic inhibition is removed, it can lead to microglial activation [15]. 
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1.5. 18 kDa Translocator Protein 
Benzodiazepines are one of the most commonly prescribed class of drugs. In the CNS they 
bind to a specific benzodiazepine alosteric binding site on the γ-aminobutyric acid (GABA)A 
receptor complex modulating the GABAA-regulated opening of Cl
- channels that is responsible 
for the inhibition of neuronal activity. In addition, another type of benzodiazepine binding site 
was identified in 1977 by Braestrup et al. [16] where they noticed that the benzodiazepine 
diazepam had a high affinity for the mitochondrial fractions of rat kidney. This ‘peripheral’ 
diazepam binding site was shown to be abundantly distributed in the peripheral tissues and was 
defined as peripheral-type benzodiazepine binding site or peripheral benzodiazepine receptor 
(PBR). Subsequent studies demonstrated the presence of PBR in glial and in ependymal cells of 
the brain [17]. It was also demonstrated that this “peripheral”-type benzodiazepine site for 
diazepam was pharmacologically, anatomically, structurally, and physiologically distinct from 
“central” benzodiazepine binding site [18]. 
A new name ‘TSPO’ was later proposed by a focus group in 2006 [19], being the peripheral 
benzodiazepine receptor renamed to 18 kDa translocator protein (TSPO). This new 
nomenclature aims to better represents its subcellular role (or roles) as a cholesterol translocator, 
its putative tissue-specific function (or functions) and its molecular weight [19, 20]. TSPO is a 
large transmembrane protein complex found at high levels on the outer mitochondrial membrane 
of the cells in the peripheral organs, such as heart, kidney lung, adrenal cortex, salivary gland, 
testis or ovaries [21-23]. It is also founded, but at low levels, primarily associated with the glial 
cells in the normal brain [24].  
 
1.5.1. Structure 
TSPO is an 18 kDa protein consisting of 169 amino-acids and is highly hydrophobic and 
rich in tryptophan  [10]. TSPO, at a subcellular level, is present mainly on the outer membrane of 
mitochondria, specialy at contact sites between the inner and outer membrane, where the 
translocator protein is particularly enriched. These sites are known as the mitochondrial 
permeability transition pore (MPTP) and are formed by at least three different subunits on the 
mitochondrial outer membrane (Figure 1.2): (1) the isoquinoline binding protein of 
18 kDa (TSPO); (2) a voltage-dependent anion channel of 32 kDa (VDAC); and (3) an adenine 
nucleotide transporter of 30 kDa (ANT) [5, 25]. 
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Figure 1.2 Structures of TSPO as a hetero-oligomeric complex. This multimeric complex consists at least of three 
different subunits, including the isoquinoline binding protein of 18 kDa (TSPO), a voltage-dependent anion channel 
of 32 kDa (VDAC) and an adenine nucleotide transporter of 30 kDa (ANT) Adapted from [5]. 
 
Thus, TSPO has a putative five transmembrane helical structure (Figure 1.2) forming a 
hetero-oligomeric complex present in mitochondria of astrocytes and microglia (Figure 1.3). In 
association with the VDAC and the ANT contains inner and outer membrane contact sites to 
enable the passage of lipophilic molecules through the intermembrane space [21]. 
 
 
Figure 1.3 Schematic diagram of the hetero-oligomeric complex localized on the outer mitochondrial membrane of 
astrocytes and microglia. Obtained from [4]. 
 
1.5.2. Function 
Decades of studies of TSPO in mammals showed many physiological functions that can be 
attributed to TSPO such as cell grow and proliferation, steroidogenesis, bile acid synthesis, 
calcium flow, chemotaxis and cellular immunity, heme biosynthesis, and mitochondrial 
respiration and apoptosis [24]. Amongst the physiological functions of TSPO, steroidogenesis is 
the best well-known. TSPO is enriched in steroid synthesising tissues such as the adrenal gland 
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and the testis, where TSPO mediates cholesterol transport from the outer to the inner 
mitochondrial membranes [26]. Its presence at the mitochondrial permeability transition pore 
(MPTP) also implicates TSPO in the regulation of necrotic and apoptotic cell dead as ligands that 
are able to cause opening of the MPTP result in the induction of apoptosis [27]. Cell proliferation 
in cancer cell lines is also inhibit by TSPO ligands, which cause an arrest of the cells at the G1/G0 
phase of the cell cycle, leading to the inhibition of the progression of the cells to the S and G2/M 
phase, where cell proliferation occurs [28]. Due to TSPO expression on microglia and other 
immune cells, this protein also plays a role in immune regulation. 
The functions of TSPO in the CNS are not clearly known [29]. Under normal physiological 
conditions, the levels of TSPO in the CNS are very low and limited to glial cells (astrocytes and 
microglia). But, it is thought that this receptor is involved in neurosteroid synthesis [30], 
regulation of mitochondrial function [10] and modulation of neuroinflammation in microglial 
cells [4]. Even though the function of TSPO in CNS is not yet entire clear, several studies have 
focused on changes in TSPO expression in a number of CNS disorders [3, 4, 25, 31]. 
 
1.5.3. TSPO in neuroinflammation 
As mentioned before, TSPO is present at very low levels in normal brain, limited to glial 
cells, but it is upregulated at sites of injury and inflammation [32]. TSPO is expressed by the 
mitochondria of activated microglial cells in response to a diversity of insults and pathogens. This 
process is not exclusive of microglia and can also be found on macrophages in response to 
inflammation throughout the body, e.g. associated with tumoral activity [5, 32]. Similarly to 
macrophages, microglial cells respond to any pathological event, through the production and 
release of pro-inflammatory cytokines (Figure 1.4).  
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Figure 1.4 Schematic diagram of function and mechanism of 18 kDa translocator protein (TSPO). Obtained 
from [4]. 
 
There is a range of synthetic TSPO ligands whose binding profile will potentially aid in the 
understanding of the TSPO binding sites and should help to determine any conformational 
changes in the TSPO protein that may occur in neuroinflammation and in various CNS disease 
states. TPSO ligands have the potential to be used in vivo and post-mortem analyses of a variety 
of CNS diseases including AD, PD, HD, multiple sclerosis, and mood disorders. It makes TSPO 
as an ideal and sensitive biomarker for microglial activation in neuroinflammatory processes.  
These outcomes have encouraged researchers to develop radioligands for TSPO. Although 
new probes are currently being developed to visualize this receptor, [11C]PK11195 remains the 
most widely used radiotracer for PET imaging of the TSPO benefiting from a significant clinical 
experience and important results in a number of  neuroinflammatory and neurodegenerative 
diseases [5, 33]. 
 
1.5.4. TSPO ligands 
As a consequence of the marked upregulation of TSPO in active disease states, it becomes 
an attractive target for in vivo imaging of disease progression using functional imaging modalities 
such as PET [4]. The TSPO is now considered a significant therapeutic and diagnostic target 
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promoting a substantial effort in TSPO ligands development.  
Radioligands for TSPO can be divided in seven chemical classes or entities [2], including 
benzodiazepines (1), isoquinoline carboxamides (2), indoleacetamides (3), vinca alkaloids (4), 
oxodihydropurines (5), phenoxyarylacetanides (6), and imidazopyridines and bioisoteric structures 
(imidazopyridines and pyrazolopyrimidines) (7). Examples of some TSPO-binding ligands from 
these classes are shown in Figure 1.5. 
 
 
Ro5-4864 (1) 
 
(R)-PK11195 (2) 
 
SSR180575 (3) 
 
Vinpocetine (4) 
    
 
AC-5216 (5) 
 
DAA1106 (6) 
 
CLINME (7a) 
 
DPA-713 (7b) 
Figure 1.5 Chemical structures of some TSPO-selective compounds, Ro5-4864 (1), (R) PK11195 (2), SSR180575 (3), 
Vinpocetine (4), AC 5216 (5), DAA1106 (6), CLINME (7a), and DPA 713 (7b). 
 
Benzodiazepines are a class of drugs known for being extensively prescribed for the relieve 
of anxiety and insomnia. They are also considered sedative and anticonvulsant because of their 
pharmacological effects (e.g. diazepam). After the discovery that diazepam binds with relatively 
high affinity to both TSPO and GABAA receptors in rat brain, new benzodiazepine derivatives 
began to appear aiming at establishing the difference between these two types of receptors. The 
benzodiazepine derivative [11C]Ro5-4864 (4’-chlorodiazepam), was synthesised at the same year 
as [11C]PK11195 and it was the first molecule able to discriminate “peripheral” from “central” 
benzodiazepine binding sites [2]. It was a 4’-chloro derivative of diazepam and was found to bind 
with high affinity to TSPO derived from rat kidney and with low affinity to GABAA [34]. 
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In 1983, Lefur and co-workers detailed the isoquinoline carboxamides as a new class of 
TSPO radioligands in addition to benzodiazepines [35]. The isoquinoline carboxamides (Figure 
1.6) are structurally different from benzodiazepines and have a higher affinity for TSPO than for 
GABAA. The first isoquinoline carboxamide synthesised in 1984 was PK11195 (more 
information in section 1.6) and since then it has found numerous applications in a number of 
animal and clinical studies. 
 
 
(R)-[11C]PK11195 (2) 
 
[11C]PK11211 
 
[11C]PK14105 
 
[18F]PK14105 
Figure 1.6 Chemical structures of isoquinoline carboxamides. 
 
There has been a wide range of ligands developed over the years that show high affinity to 
the TSPO binding site. All share some common features [36] including a fused bicyclic aromatic 
system containing two electronegative boundaries and a freely rotating aromatic ring. Moreover, 
many ligands also contain a third electronegative group surrounded by lipophilic substituents 
[36]. Development of new TSPO ligands is also underway with the aim of finding more selective 
and specific compounds based of those structures. From those, compounds with favourable in 
vivo binding properties and kinetics could be used to increase our understanding of the normal 
functioning of the TSPO and the chemical pathways underlying several pathological conditions. 
 
1.6. (R)-[11C]PK11195 
PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline] was the first 
non-benzodiazepine high-affinity selective TSPO ligand (KI=9.3 nM) and was labelled with 
carbon-11 ([11C]PK11195) as a probe for PET imaging [37]. It was discovered in 1984 and named 
after a French company, Pharmuka [38]. 
In 1994, Shah et al. [39] synthesised and compared in vivo the R and S enantiomer of 
[11C]PK11195 (Figure 1.7) in rats with a cortical focal lesion. This study showed a twofold higher 
affinity of the (R)-[11C]PK11195 enantiomer, making it advantageous over the (S)-[11C]PK11195 
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for imaging studies. With its nanomolar binding affinity, it remains today the most widely used 
ligand for TSPO imaging and is regarded as the prototypal reference for new compound 
development [5]. 
 
 
(S)-[11C]PK11195 
 
(R)-[11C]PK11195 
Figure 1.7 Chemical structures of (R)- and (S)-[11C]PK11195. 
 
PK11195 presents favourable kinetic proprieties that allow its use as an in vivo ligand 
including the ability to permeate the blood brain barrier (BBB) by passive diffusion [37] with an 
extraction from blood to brain of over 90%. Studies of whole-body distribution and metabolism 
of (R)-[11C]PK11195 in humans [40], showed a large inter-individual variation in the amount 
radiolabelled metabolites in plasma. Whole-body distribution of (R)-[11C]PK11195 showed the 
highest radioactivity levels in urinary bladder, adrenal gland, liver, salivary glands, heart, kidneys 
and vertebral column. (R)-[11C]PK11195 seems to be eliminated through both the renal and 
hepatobiliary systems. 
(R)-[11C]PK11195 exhibits high affinity for the TSPO in all species [41], however newer 
radioligands are beginning to appear as an alternative to PK11195 [34, 42, 43]. They have, so far, 
failed to replace it due to inadequate pharmacokinetic proprieties, poor bioavailability toward 
brain tissue or a high level of nonspecific binding [33]. All these new ligands share some common 
features that allow researchers to have a better insight of the TSPO binding domain, thus 
opening the door for the development of better, more selective and specific tracers that could be 
available in the future. 
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1.6.1. PET imaging studies of TSPO in human diseases 
Overexpression of TSPO can be detected in vivo by PET imaging with selective 
radioligands such as [11C]PK11195 [2, 3, 29, 37]. With the evidence that [11C]PK11195 binding 
potential (BPND) increases with the activation of microglia [44], this tracer has been used in a wide 
range of human CNS diseases that involve some degree of inflammation such as Parkinson’s 
disease (PD), Huntington’s disease (HD), multiple sclerosis , Alzheimer’s disease (AD), 
Dementia, Rasmussen’s encephalities, amyotrophic lateral sclerosis, infectious diseases (HIV and 
herpes encephalitis), and neuropsychiatric disorders such as schizophrenia [37]. Thus, the 
assessment of TSPO with PET provides an in vivo tool to monitor the progression and severity of 
neuroinflammation, providing a useful biomarker for several active CNS diseases. 
 
Parkinson’s disease (PD) 
Parkinson’s disease is the second most common neurodegenerative disorder of the aged 
and is associated with the motor symptoms of tremor, bradykinesia, and rigidity. PD is 
characterised by the extended loss of dopaminergic neurons in the substantia nigra pars 
compacta, resulting in a deficiency of dopamine in the striatum. PD is the most common of a 
group of parkinsonian movement disorders that also includes multiple system atrophy, 
corticobasal degeneration, and progressive supranuclear palsy [45].  
Several studies suggest a close relationship between neurodegeneration and 
neuroinflammation in PD, and further clues regarding the role of activated microglia has also 
come from in vivo PET imaging studies [3]. Inflammation through activated microglia can be 
measured directly using [11C]PK11195 and this tracer has paved the road to in vivo animal and 
human PET studies for measuring neuroinflammation in PD [45]. 
Two PET studies have reported a significant increase in (R)-[11C]PK11195 binding in both 
striatal and extrastriatal regions in PD patients when compared to normal controls (Figure 1.8) 
[46]. In one of these studies, levels of putamen dopamine transporter binding were inversely 
correlated with levels of midbrain microglial activation. 
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Figure 1.8 PET scans with [11C]PK11195 of a healthy subject and a Parkinson’s disease patient. Mild microglial 
activation is seen in the thalamus of the healthy control but a significantly raised activation is evident in the midbrain 
and striata of the PD patient. Obtained from [46]. 
 
Additional, extensive binding of (R)-[11C]PK11195 has been observed in patients with the 
atypical syndrome multiple system atrophy [47]. Taken together these findings support the 
hypothesis that neuroinflammatory responses, as evidenced by activation of microglia, contribute 
to neuronal loss in PD and other neurodegenerative diseases. 
 
Huntington’s disease (HD) 
Huntington’s disease is an autosomal, dominant inherited progressive neurodegenerative 
disorder associated with motor, cognitive, and psychiatric symptoms. HD is caused by an 
abnormal polyglutamine-repeat expansion on the IT15 gene that codes huntingtin, and involves 
the progressive loss of medium spiny dopaminergic receptor-bearing striatal GABA-ergic 
neurons [48].  
In vivo studies evidence an increase in (R)-[11C]PK11195 BPND in the striatum and cortical 
regions in symptomatic HD patients when compared with healthy controls [49]. They suggests 
that in manifest HD patients, the observed significant increase of (R)-[11C]PK11195 BPND in the 
striatum, hypothalamus, and various cortical regions is correlated with greater disease burden and 
higher motor disability. More studies using this radioligand have also found increased microglial 
activation in symptomatic HD patients and in manifest HD patients when compared with healthy 
control ([3] and references inside), and interestingly, this microglial activation in the striatum and 
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regions related to cognitive function has been shown to predict the 5-year disease clinical onset in 
pre-manifest HD patients.  
These findings show that microglia activation is an early event in the HD disease course, 
and may have a pathogenic involvement that is associated with progression of the disease.  
 
Multiple Sclerosis 
Multiple sclerosis is a disease characterised pathological by inflammatory demyelination and 
axonal transection, being the most common cause of non-traumatic disability in young 
adults [50].  
The presence of activated macrophages in areas of demyelination and the presence of 
myelin debris within the cytoplasm has been a strong argument for a direct role of this cell type in 
multiple sclerosis. Activated microglia involvement in the immune response of multiple sclerosis 
has long been proposed [51]. Consequently, pathological aspects of multiple sclerosis such as 
neuroinflammation, demyelination, and neurodegeneration may be explored in vivo by PET 
imaging studies with radiolabelled (R)-[11C]PK11195 ligand. These studies have proved that the 
inflammatory processes and microglia are actively involved in multiple sclerosis (Figure 1.9) [3].  
 
 
Figure 1.9 Increased [11C]PK11195 binding potential (BPND) in a Multiple Sclerosis patient (A) when compared to a 
healthy normal control (B). Color bar represents intensity of [11C]PK11195 tracer binding. Obtained from [3]. 
 
In conclusion, [11C]PK11195 and PET are able to demonstrate inflammatory processes 
with microglial involvement in multiple sclerosis. 
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Alzheimer’s disease (AD) 
Alzheimer’s disease is defined neuropathologically by the presence of neurofibrillary tangles 
and plaques associated with tau and β-amyloid (Aβ) protein deposition.  
Over the last decades, there was increasing evidences that neuroinflammation represents a 
crucial part in the pathogenesis of AD, such as in other neurodegenerative diseases. The 
localisation of microglia and β-amyloid plaques has been widely reported in pathological 
examination of AD suggesting that neuroinflammation may play a role in the pathogenesis 
and/or delay the progression of the disease. Activated microglia present at sites of aggregated Aβ 
deposition in the brains of AD patients may contribute to Aβ removal [52]. Nevertheless, the 
secretion of cytokines associated to the activation of microglia also can contribute to tissue 
damage and apoptosis [53].  
Other hypotheses suggest that microglial activation in AD occurs as a consequence of 
extracellular Aβ deposition or that it serves as a triggering factor for Aβ deposition in the initial 
stage of the disease. 
[11C]PK11195 has been used to image AD patients with PET but results, so far, have not 
been completely clear. One of the first study of AD with [11C]PK11195 was negative must 
probably due to the relatively high level of non-specific binding, that resulted in non-favourable 
signal strength [54]. A more recently study using the R-enantiomer of this ligand, 
(R)-[11C]PK11195 [55], showed a moderately increased binding potential (Figure 1.10). 
 
Figure 1.10 Significant increase of (R)-[11C] PK11195 uptake in Alzheimer’s Disease patients when compared with 
control. Adapted from [55] 
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However, more research with longitudinal assessment of microglial activation in humans is 
needed to understand its role as a consequence or an influence factor for the progression of the 
disease. 
 
1.6.2. PK11195 limitations 
With the exception of the earliest studies, the vast majority of PET imaging studies on 
TSPO in human diseases have been performed with the (R)-enantiomer of [11C]PK11195,. 
Although it is recognised that (R)-[11C]PK11195 and even [11C]PK11195 shows increase uptake in 
a wide array of neurodegenerative disorders, there are several methodological and kinetic 
unresolved issues that limit the interpretation and potential use of this TSPO radioligand. 
There is a lower than desirable binding potential that has attributed to the low receptor 
affinity and relatively low total brain uptake, which results from substantial binding of the tracer 
to other parts of the body. It suffers from high plasma protein binding and high non-specific 
binding related to its high lipophilic nature (logP = 3.4) [56]. Less than ideal penetration of the 
BBB and low brain uptake leads to a poor signal-to-noise ratio on PET imaging. Other 
complicating factors are the highly variable kinetic behaviour, and sensitivity and specificity issues 
which have precluded the development of a standard quantitative method for analysis applicable 
to all subjects. Therefore, the research field is open to find alternatives to PK11195 that can 
perform better for the quantification of TSPO expression in vivo. [5]  
In addition to these disadvantages, the short half-life of 11C (20.4 minutes) limits its use in 
routine clinical practice of PET imaging in centres without an on-site cyclotron facility. 
 
1.7. Molecular Imaging 
Advanced diagnostic techniques in the field of biomedical research aim to identify and 
quantify in vivo biological and biochemical processes at the cellular and molecular level. The 
intense research effort being made in this area has prompted for a new field called molecular 
imaging (MI) that includes techniques so diverse as magnetic resonance imaging (MRI), 
computed tomography (CT), ultrasound (US), optical and nuclear imaging [57, 58]. Each 
modality has its own advantages and disadvantages, but nuclear imaging has unrivalled properties 
when compared with other techniques as it can directly visualize molecular events at nanomolar 
level with high sensitivity and specificity [59]. In recognition to this, nuclear imaging techniques 
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such as positron emission tomography (PET) and single photon emission tomography (SPECT) 
are increasingly being used in the clinical setting for applications in oncology, cardiology and, of 
course, neurology. 
Particularly in neurology, PET can provide clinicians with the ability to image in vivo 
regional cerebral functions with radiotracers (radiopharmaceuticals) labelled with positron-
emission isotopes introduced into patients. As an important and useful technique for diagnosis, 
therapeutic planning and research, PET requires specific probes radiolabelled with short-lived 
positron-emitting nuclides. Therefore, the full potential of PET strongly depends on the 
availability of proper radioligands for the cellular and molecular processes that are of interest, as 
well as, on the development and optimisation of new ones when a suitable probe is not available. 
 
1.7.1. Molecular imaging probe concept 
The requirements for a successful probe for molecular imaging (MI) include high affinity 
and specificity for the intended molecular target as well as the ability to overcome the relevant 
biological barriers (Figure 1.11). Also important are the kinetics of binding to the target, blood 
clearance and the presence of metabolites that can access the specific compartment and make 
quantification impossible. 
 
 
Figure 1.11 Several key criteria for probes in molecular imaging. Adapted from [58]. 
 
The choice of a molecular target with sufficient density to allow a strong specific signal and 
easy access for the MI probe is also fundamental. In PET, the selection of a suitable nuclide with 
an adequate half-life considering the synthesis time and the kinetics of the process being followed 
is a critical issue.  Finally, the choice of labelling position is important as it has to maintain the 
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physicochemical characteristics of the compound being labelled and also be resistant to 
metabolism that could remove the label from the probe and invalidate the study. 
 
1.7.2. Principles of Positron Emission Tomography 
Positron emission tomography (PET) is a powerful scientific and clinical tool and is one of 
the most sensitive techniques to image non-invasively, molecular pathways and interactions  in 
vivo [60]. The full potential of PET is made possible by the availability of very specific and 
selective ligands for critical molecular targets that are relevant for a wide range of diseases [61]. 
The PET technique is based on intravenously administration in animals and/or humans a 
radiopharmaceutical compound labelled with a short-live positron-emitting radionuclide, in order 
to acquire 3D images of functional process by detecting and quantifying the distribution of the 
labelled tracer in the body [60]. Among the numerous short lived positron-emitting isotopes 
available, Carbon-11, Fluorine-18, Nitrogen-13 and Oxygen-15 (physical proprieties in Table 1.1) 
are the most important considering the prevalence of these elements in organic molecules making 
them very attractive to be incorporated into biomolecules. This allows the labelling to take place 
without affecting the physicochemical properties of the parent molecule a feature that is critical 
for the success of the study. 
 
Table 1.1 Physical Proprieties of the most common short lived positron-emitting isotopes [62]: Carbon-11 (11C), 
Fluoride-18 (18F), Nitrogen-13 (13N) and Oxygen-15 (15O). *EC: Electron capture. 
Radioisotope Half-life Decay mode Max. Energy Mean Energy Max. Range 
 (minutes) Decay product (MeV) (MeV) (mm) 
Carbon-11 20.4 
100% β+ 
Boron-11 
0.96 0.386 4.1 
Fluorine-18 109.8 
97% β+ 3% EC 
Oxygen-18 
0.69 0.250 2.4 
Nitrogen-13 9.98 
100% β+ 
Carbon-13 
1.19 0.492 5.4 
Oxygen-15 2.05 
100% β+ 
Nitrogen-15 
1.70 0.735 8.0 
 
1.7.2.1. Production of radiolabelled compounds for PET 
The production of radiolabelled compounds for positron emission tomography with short-
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lived positron-emitting radionuclides (e.g. Carbon-11, Fluorine-18, Nitrogen-13 and Oxygen-18) 
is limited to sites with on-site cyclotron because of their short half-life. In fact, inside the list of 
radionuclides mentioned above (Table 1.1), only the Fluorine-18 (18F) can be used in PET sites 
without on-site cyclotron through registered 18F-labelled radiopharmaceuticals distributions. For 
the other three, the production has to be performed in a medical cyclotron on-site, requiring 
dedicated equipment and specially trained and qualified personnel. 
 
1.7.2.2. The detection principle 
Positron emission tomography relies on the use of positron emitting atoms bond to 
organic molecules as tracers for endogenous physiological activity. Positron emitters are 
characterized by an excess of positive charges in their nuclei, and decay towards a stable state. 
This leads to a transformation of a proton into a neutron, having emission of a neutrino (n) and a 
positron (β+).  
The imaging of regional tracer concentration is associated to the unique properties of 
positron decay and annihilation. Because of the energy released by the electronic transition, when 
emitted, the energetic positron travels a few millimetres through the tissue until becomes 
thermalized by electrostatic interaction between the electrons and the atomic nuclei of the media 
and combines with a free electron to form a positronium. The positronium decays by 
annihilation, generating a pair of gamma rays which travel in nearly opposite directions with an 
energy of 511 keV each (Figure 1.12, A). The simultaneous and coincidence detection of both 
photons makes it possible the definition of a virtual axis on which the positron is annihilated with 
an electron of the medium, a few milimeters from the place of issue (Figure 1.12, B). The 
generation of these gamma rays is the basis of positron emission tomography. 
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Figure 1.12 Principle of PET detection. Radioactive probes emitting positively charged anti-electrons (positrons) are 
used as imaging agents for PET. The positron travels a short distance before it annihilates with any electron to give 
two photons of 511 keV travelling under a mutual angle of 180º. The simultaneous detection of these two gamma 
ray photons is behind of PET principle and allows in vivo quantitative 3D imaging acquisition. 
 
Thereby, when a probe containing a positron emitter is administered to an organism, high-
energy gamma rays are produced, which have a high penetration power, are able to escape from 
the body, and can be detected by an external ring of detectors as a coincident event. The 
simultaneous detection of many thousand pairs of gamma photons (511 keV each) allows the 
reconstruction of a 3D image containing information about the distribution of the radiolabelled 
probe in the organism. 
 
1.7.2.3. Cyclotron: high energy particle accelerator 
"Dr Livingston has asked me to advise you that he has obtained 1,100,000 volt protons. He also 
suggested that I add ‘Whoopee'!" Telegram to Lawrence, 3 August 1931. 
A cyclotron (Figure 1.13) is a particle accelerator capable of animating particles to energies 
that are high enough to promote nuclear reactions. The idea to curve the path of the particle 
beam of a linear accelerator (LINAC) into a spiral path and use over and over again the same 
electrode system to accelerate the particles, came from E. Lawrence. The first model was built in 
1930, and in 1931 the proof of particle acceleration was performed by Livingston [62]. This 
notable idea of these two American physicists is the base of all modern cyclotrons, making the 
cyclotron the most widely used type of particle accelerator. 
Currently, most radionuclides used for labelling PET radiopharmaceuticals are produced by 
bombardment in a cyclotron. 
Introduction 23 
 
  
Figure 1.13 General views of two cyclotrons from different eras First Livingston cyclotron in 1931 (left) and an IBA 
Cyclone 18/9 cyclotron (right).  
 
1.7.2.3.1. Principles of operation 
The basic operating principles of the cyclotron are showed in Figure 1.14. In a cyclotron, 
an electrical field is used to accelerate ions, such as H- or D-, and a magnetic field is applied to 
bend the moving charges into a spiral path.  
From a structural point of view, a cyclotron is composed by two hollow copper electrodes, 
called dees (or D’s) due to their shape, inside a vacuum chamber. The two dees are connected to 
a high radiofrequency power supply that provides a sinusoidal alternating electric field between 
the two electrodes, being the electric field null inside the two dees. The dees and their vacuum 
chamber are placed between the poles of a big magnet, fed by a coil, to produce an approximately 
uniform magnetic field perpendicular to the radial plane of dees. The negative ions are generated 
by applying a high voltage to hydrogen or deuterium gas in the ion source at the centre of the 
cyclotron, getting a constant increase in energy for each passage across the gap between dees.  
 
Figure 1.14 Schematic structure of cyclotron showing the ‘dee’ structure, the ion source and the magnet. Obtained 
from [62]. 
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The acceleration of particles (protons or deuterons) in the so-called central region begins in 
the centre, where negative ions are generated by applying high voltage to a gas (hydrogen or 
deuterium). By applying an electrical field, the negative ions are extracted from the centre of 
cyclotron (ion source) and are accelerated towards the dee and counter dee by the electrical field. 
As the ions pass through the hole of the dees, they are only subjected to the magnetic field. When 
the dee is positively charged, the counter dee is negatively charged therefore when the ion leaves 
the dee is accelerated to the counter dee, because of the reversed polarity. This process is the 
same in other dee, but the speed and the orbit radius of the ion are higher. The acceleration 
process only ends when the ion reaches the border of magnetic field, being extracted by stripping 
the electrons off the negatively charged ions and allowing the magnetic field to reverse the 
curvature of the resulting positively charged paths and to transport the particles towards the 
target. The charged ion, now positive, leaves the magnetic field and continues to target position, 
where collides with specific substances (liquid or gas), to generate the nuclear reaction. 
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Figure 1.15 Schematic top view of the main body of an IBA Cyclone 18/9 cyclotron. Negative ions are generated in 
ion source (A). The electrical current passing through the coils (B) creates the magnetic field and surrounds the four 
wedge-shaped steel sectors. The two electrodes, also called dees (C), are placed between steel sectors and the counter 
dees are placed on the edges of four steel sectors close to the dees. The negative ions are accelerated until they hit a 
stripper foil (usually graphite; E) which removes the electrons and charge positively the ion leaves the cyclotron and 
strikes the selected target (placed on F) to produce the radioisotope. Adapted from: IBA user manual. 
 
After acceleration and before the collision with the target, the projectiles energy is related 
with the radius path of the ions inside the dees. As the projectiles acquire energy, the radius of 
their path within the dees increases, with the energy of projectile expressed by the follow 
equation: 
𝐸𝑘𝑖𝑛 =
1
2
𝑞2
𝑚
𝐵2𝑟2  
 
(1) 
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where q and m are the charge and the mass, respectively, of an ion, B is the modulus of the 
magnetic field vector and r is the radius of a circular path described by the ion under the effect of 
the magnetic field force. Thus, the sum of all individual accelerations in the gaps between dees is 
the energy achieved by the ion. This energy is kinetic energy and is dependant on the nature of 
the ion and the size of the magnet. 
The actual production of radioisotopes happens at the same moment in which the beam of 
accelerated particles collides against the target nucleus resulting in the desired nuclear reaction. 
 
1.7.2.3.2. Targets 
Generally, the target materials (usually gas or liquid but can also be solid) are contained in 
special containers called target chambers, which are irradiated by the beam of accelerated 
particles. Because of the heat produced by the beam, the target is continuously cooled with water 
and helium to counterbalance this heating. The target can be made up from different materials 
(e.g. silver, aluminium). All materials must be chemically and physically inert and be able to resist 
high temperatures and pressures. Target materials can be in the solid, liquid or gaseous physical 
state, operating as a target for the nuclear reaction. It is essential that these materials (composed 
by a stable isotope) are in the most pure form. This avoids side reactions, caused by the 
impurities present. 
Targets designed for the production of the most common shot-live positron emitters 
(carbon-11, fluorine-18, nitrogen-13 and oxygen-15), have been developed over the years and are 
readily implemented in all commercial available cyclotrons. 
 
1.8. Radiochemistry 
Positron emission tomography has numerous applications in the understanding of 
biological processes in living systems. It plays an important role in understanding disease 
pathology, progression and diagnosis, and also in drug development. Fundamental for this 
technique is the production of molecules labelled with short-lived positron emitting 
radionuclides. These labelled compounds are called radioligands or radiotracers, and their 
production (synthesis) forms the basis of radiochemistry. 
Considering its ubiquity in organic molecules, carbon-11, is one of the most commonly 
used PET radionuclides. It has a short-live half-life (20.4 minutes) and, due to the versatility of 
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carbon chemistry, this radioisotope can be incorporated into virtually any organic molecule 
without significant effect on biological activity. In addition, the short half-life of 11C allows for 
repeated injections in the same subject and day. Therefore, 11C radiopharmaceuticals are being 
applied in an increasing number of applications in non-invasive investigations in humans. The 
ability to study in vivo biochemistry processes, and eventually also to follow the fate of certain 
atom in a molecule, provides science and clinical practice with important new information [63]. 
 
1.8.1. Carbon-11 
Radiochemistry with carbon-11 (11C) brings considerable challenges to radiosynthesis, due 
to the short half-life of this positron emitter. Compared to the almost 2h half-life of fluorine-18, 
the shorter half-life of 11C provides the advantage to perform repeated PET studies while 
maintaining low doses on the patients.  
Carbon-11 has a 20.4 minutes half-life and decays 99.8% by positron emission and only 
0.2% by electron capture. It decays to stable boron-11. More characteristics of 11C are showed in 
Table 1.2.  
 
Table 1.2 Characteristics of carbon-11 as a PET isotope. 
Carbon-11 (11C) 
Half-life: 20.4 minutes 
Decay Mode: 99.8% β+, 0.2% EC 
Max. Energy: 0.96 MeV 
Most Prob. Energy: 0.326 MeV 
Max. Range: 4.1 mm 
Max. Specific Activity (theoretical): 9220 Ci/µmol 
 
Due to its favourable decay characteristics (Table 1.2), 11C is considered one of the most 
interesting labelling agents for clinical as well as research use with PET. Over the last 3 decades, 
thousands of 11C labelled compounds were developed and many 11C labelling precursors have 
been used to incorporate 11C-isotopes to various and different molecules. 
Figure 1.16 lists the chemical synthesis of some of the most important carbon-11 
precursors. In the present work, we are mainly focused of the pathways steaming from the 
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precursors [11C]methyl iodide ([11C]CH3I) and [
11C]methyl triflate ([11C]CH3OTf). 
 
14N(p,α)11C
11CO2
11CH4
0.5% O2
5% H2
H2, Ni, 390º
LiAlH4/THF
11CH3I
11CH3O-
HI
I2, 720ºC
11CH3OTf
CF3SO3Ag,
180ºC11CH3I ‘Wet’ method production way
11CH3I gas phase production way
 
Figure 1.16 Pathways to produce 11C-labelling precursors. [11C]methyl iodide, the most common, can be synthesised 
by two different methods: the so called ‘wet’ method with reduction of 11CO2 to methanol by lithium aluminium 
hydride (green) and the “gas phase” by the 11CH4 pathway, or by the reduction of CO2 to CH4 (yellow). 
 
1.8.2. Production of 11C 
The first production of the short-lived positron emitting radionuclide carbon-11 was made 
by Crane and Lauritsen in 1934 [63]. Their work aimed to investigate the physical properties of 
11C and demonstrated that this radionuclide decays by positron emission to the stable nuclide 
boron-11 (11B). Due to its short half-life, radiopharmaceuticals labelled with 11C are not easy to 
transport from manufacturing centres to surrounding hospitals. Consequently, this nuclide began 
to receive increasing attention in medical application only when cyclotrons and PET scanners 
begun to be installed at the same site.  
Several nuclear reactions can be used to produce 11C (Table 1.3), amongst these the 
14N(p,α)11C reaction, using nitrogen gas as target material (irradiated material), is by far the most 
commonly used. High yields of 11C production are obtained by this reaction if a small amount of 
oxygen (<2%) or hydrogen (5-10%) is available in the target gas. The primary precursors 
[11C]carbon dioxide ([11C]CO2) and [
11C]methane ([11C]CH4) are, respectively, formed.  
The in-target production of [11C]CO2 is generally achieved with higher radiochemical yields, 
while the specific activity is lower compared to the production of [11C]CH4 [64]. 
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Table 1.3 Nuclear reactions used to produce carbon-11. Natural abundance of the irradiated stable isotope is listed 
in the last column. Obtained from [65]. 
Nuclear Reaction Useful Energy Range (MeV) % Natural Abundance 
11B(p,n)11C 5 - 20 80.1 
10B(d,n)11C 3 – 12 19.9 
12C(p,pn)11C 20 – 50 98.9 
14N(p,α)11C 7 – 15 99.6 
14N(d,n4He)11C 10 – 15 99.6 
12C(3He,4He)11C 7 – 15 98.9 
 
Although there are several ways to produce 11C described in literature [63], the most widely 
used is based on the so-called ‘wet’ method in which the [11C]CO2  is reduced to a [
11C]lithium 
methoxide salt with lithium aluminium hydride solution (LiAlH4) and then by addition of 
hydiodic acid (HI) [11C]methyl iodide ([11C]CH3I) is produced and then distilled to produce the 
11C-methylating agent. 
The [11C]CO2  is produced, as mentioned above, using the 
14N(p,α)11C reaction by 
irradiation of a material target composed by nitrogen and small amounts of oxygen. This was the 
procedure used for this work for the optimisation of the 11C-labelling of [11C]PK11195. 
 
1.9. Half-life of the radionuclide 
As mentioned above, the half-life of the radionuclide is a key factor in the production of 
PET radiopharmaceuticals. Overall, the half-life of the radionuclide should be long enough for 
the radiolabelling process and the time frame of the imaging procedure and, ideally, the 
radiolabelled compound should be produced within 2-3 half-lives of the radionuclide. This is 
important to maintain high radiochemical yields and high specific activity. 
Furthermore, the stoichiometric ratio between the precursor for labelling material and the 
radioactive precursor should be chosen in the range between 10000 and 10, due to the low mass 
of radioactive agent. As a result, the starting radiolabelled reagent is rapidly consumed in a 
pseudo-first order reaction kinetics, independently of its concentration. 
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1.10. Specific Activity 
Medical applications of radiopharmaceuticals labelled with short-live positron emitters 
require high specific activity (SA) of the compounds, i.e. they should have a high concentration 
of radioactivity per unit mass. Specific activity is arguably one of the most important parameter 
associated with the development and production of 11C labelled compounds where ‘cold’ carbon 
can contaminate the preparation at various steps in the synthesis. With advances in PET 
applications, there is an increasing demand for novel more specific labelled radioligands, mainly 
with carbon-11 and fluorine-18, and specific activity has become an important issue. This is 
particularly important when the radionuclide is incorporated into a radiolabelled compound that 
is used to probe some physiological process that has low density of target molecules in the body 
such as receptors, enzymes, gene expression, monoclonal antibodies, etc. [65].  
The specific activity of a radiopharmaceutical can be defined as the ratio between 
radioactivity of an isotope and the amount of carrier (which is normally the non-radioactivity 
counterpart of the isotope or labelled compound). According to the more updated terminology 
that is recommended by the IUPAC [66], the concept of specific activity for a certain nuclide, or 
a mixture of nuclides, is defined as the activity of a radionuclide divided by the mass of all 
radioactive and stable nuclides isotopic with the element involved. Although the theoretical 
specific activity (or specific radioactivity) for Carbon-11 is 341.14 TBq/μmol 
(9220 Ci/mmol1) [65], these values are usually very high compared with SA values of 
radiopharmaceutical obtained at end of synthesis (EOS). This decrease of SA is due to the 
dilution process with non-radioactive isotope (xC), that occurs not only during radionuclide 
production and their incorporation in a compound (radiosynthesis), but also in reagents, gases, 
impurities in target materials and many others factors. It is also noted that, if it is possible to 
decrease SA by diluting the radioligand with non-radioactive compound, the opposite (SA 
increase) is not possible. Thus, if high specific activities values are obtained during radiosynthesis, 
a radioligand with a pre-determined SA can be prepared by simple addition of the accurate 
amount of non-radiolabelled compound. It is important to note that these non-radioactive 
isotopes undergo the same chemical transformations of their radioactive conterparts. 
When this ‘cold’ contamination of labelled compound is significant and the SA is far from 
the theoretical value, the physical decay of the 11C radionuclide affects the specific activity by a 
factor of two for every 20.4 minutes (11C half-life). Consequently, synthesis time becomes an 
important factor for obtain good specific activities, since it declines rapidly with time. The total 
                                                          
1 1 Ci = 3.7 x 1010 Bq 
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amount of radioactivity injected is also related with SA, due to the total quantity of radiolabelled 
and non-radiolabelled compound administrated. 
This competition between radiolabelled and non-radiolabelled compounds may have a 
negative effect on the concentration of radioactivity in the target tissue, and it can produce 
undesired pharmacodynamic and/or toxic effects, as well as the receptor saturation and 
internalization. Hence, high SA is crucial to provide sufficient contrast in images between the 
target tissue and its surrounding. 
As mentioned above, SA decreases rapidly with time considering that, as time passes, the 
number of non-radioactive isotopes remains constant while radioactivity decays by a factor of 
two, in case of carbon-11, for each 20 minutes. For this reason, it is mandatory to calculate the 
SA by decay correction to a specific time point such as end of bombardment (EOB), end of 
synthesis (EOS), or time of injection (TOI). Therefore, radiopharmaceutical synthesis and quality 
control with carbon-11 labelled compounds must be carried out in the shortest possible time.  
In summary, the specific activity values of cyclotron produced radioisotopes depend on 
several factors, such as: 
- Materials that these radioisotopes are in contact during irradiation and target transfer to 
the synthesis hot-cells; 
- The quality of the irradiated material and the amount of radioactivity produced during 
irradiation; 
- Sources of stables isotopes from the surface of the target chamber and tubing; 
- Contamination of stable isotopes from the irradiated material; 
- Quality and quantity of reagents used in the chemical transformations; 
- Low purity of inert gases (helium or nitrogen) used in synthesis steps. 
All these factors affect the final SA values of a radiopharmaceutical. In particular for 
carbon-11, those factors assume great importance because of its short half-life and the 
competition by side reactions with environmental carbon-12 (12C) sources (especially when the 
radioactive precursor used is [11C]carbon dioxide ([11C]CO2)). This is why the main goal of the 
present work - optimisation of specific activity of radiolabelled compounds with carbon-11, most 
particularly [11C]PK11195 - is a relevant and most important challenge for the successful use of 
these compounds for in vivo molecular imaging with PET. 
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Materials and Methods 
2.1. Background 
The Radiochemistry and Cyclotron Laboratory of ICNAS, enables this multidisciplinary 
institute to produce a variety of pharmaceuticals labelled with short-lived positron emitters. 
Production operations are assigned to a University owned company ICNAS-Produção 
Unipessoal, Lda (ICNAS-P) that holds all necessary licences for GMP pharmaceutical 
manufacturing and has achieved Marketing Authorization for its first commercial product 
(Fluodesoxiglucose [18F] UC) in December 2011. Besides distribution at national level for 
hospitals and imaging centres, ICNAS-P also produces positron emitting tracers for internal use 
at ICNAS to support ongoing pre-clinical and clinical research studies as well as its own R&D 
projects. ICNAS-P has state-of-the-art equipment for radiopharmaceutical production, 
dispensing and packaging including an IBA Cyclone 18/9 cyclotron, 2 fully-equipped GMP Class 
C production labs, 4 hot-cells and 5 modules and one robotic arm for automatic 
production/dispensing of radiopharmaceuticals. The production facility is completed by a full 
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Quality Control lab that includes 2 high performance liquid chromatography (HPLC) systems, 1 
gas chromatograph (GC), 1 radio thin layer chromatograph (radio-TLC) system 1 dose calibrator 
and a High-Purity Germanium (HPGe) gamma spectrometer.  
The synthesis optimization of (R)-[N-Methyl-11C]PK11195 is well in-line with the R&D 
strategy of ICNAS as outlined by its Scientific Council and is expected to provide researchers 
with a crucial tool for in vivo molecular imaging of inflammation both in animal models as well as 
in human studies. The project fits well the objectives of the Integrated Master in Biomedical 
Engineering and is expected to take advantage of the scientific knowledge accumulated by the 
candidate during the course of the studies. 
 
2.1.1. The captive solvent loop 
A particular method for the 11C-methylation of precursors with [11C]CH3I was developed 
by Wilson et al. [67] as a part of the synthesis of [11C]raclopride (a D2-like dopamine receptor 
ligand). The originality of this method is to use of an HPLC injection loop which serves as 
reactor for radiosynthesis (Figure 2.1).  
 
 
Figure 2.1 Apparatus and flow diagram for trapping [11C]methyl iodide on HPLC loop, pre-charged (coated) with a 
non-radioactive precursor. The labelling reaction takes place instantly before injection into an HPLC 
semi-preparative column for purification. Obtained from [67]. 
 
The non-radioactive (cold) precursor is dissolved in a small volume of solvent (80 μl), and 
then slowly injected into a 2 ml stainless steel loop enabling it to coat the inner surface of the 
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tube. [11C]methyl iodide is then swept into the HPLC loop with the precursor solution by a 
stream of N2 gas (8 ml/min) at room temperature as it becomes efficiently trapped by the cold 
precursor solution and enables the reaction to take place. Once the reaction is complete, the 
mixture is readily injected into a semi-preparative HPLC column to purify the synthesised 
products. Since no vials, transfer lines, cooling, heating, or sealing valves are required, this 
technique simplifies handling and minimizes losses permitting the achievement of significantly 
higher yields. 
 
2.1.2. Quality control of PET radiolabelled compounds 
Before a PET radiolabelled compound can be administrated to a patient, there is the 
requirement to produce a compound that is of pharmaceutical quality. Care must be taken to 
ensure that the radiolabelled compound is suitably labelled, purified, formulated and sterilized. 
Quality control procedures for radiopharmaceuticals [68] are similar to those applied to 
non-radioactive pharmaceuticals, and are separated into two categories of tests: physicochemical 
tests and biological tests. The physicochemical tests establish the level of chemical, radiochemical 
and radionuclidic purity and determine the pH, osmolality, activity, concentration and other 
physical properties. The biological tests establish the sterility, apyrogenicity, and toxicity of the 
sample. 
 
2.2. Aims 
The aim of this work is the automation and optimisation of the radiosynthesis for 
(R)-[N-Methyl-11C]PK11195. Full automation, i.e. synthesis, purification and reformulation of 
[11C]PK11195 (notation used from this point, which refers to (R)-enantiomer; 
(R)-[N-Methyl-11C]PK11195) with quality for human injection  in the shortest possible amount of 
time, is required. Also important is the optimisation of the synthesis parameters to ensure the 
reproducibly and reliability of several successive radiosynthesis per day. The study of main 
sources of stable isotopes (non-radioactive) of carbon in the production of [11C]CH3I through the 
‘wet’ method, and their ‘elimination’ from the synthesis is a critical issue to be optimized, to 
ensure that the final product has the best possible specific activity. This effort is important in 
establishing general guidelines for the optimisation of SA values in the production of 
(R)-[11C]PK11195 and others 11C-labelled compounds methylated via this method. 
To achieve a final preparation of [11C]PK11195 suitable for human injection, several steps 
36 CHAPTER 2 
 
are required: 1) production of carbon-11 in a cyclotron by irradiation of a N2+0.5% target; 
2) conversion of the [11C]CO2 formed in the cyclotron to [
11C]methyl iodide ([11C]CH3I) or 
[11C]methyl triflate ([11C]CH3OTf); 3) 
11C-methylation of the precursor 
((R)-[N-Desmethy]PK11195) in a captive solvent loop; 4) purification in a HPLC reverse-phase 
system and 5) reformulation in 10% EtOH+90%NaCl 0.9% injectable solution. 
 
2.3. Automation of radiosynthesis for (R)-[N-methyl-11C]PK11195 
2.3.1. General 
All irradiations were performed on a IBA Cyclone 18/9 cyclotron (IBA, Louvain-la-neuve, 
Belgium) using high energy (18 MeV) protons. 
Production of [11C]CH3I and conversion to [
11C]CH3OTf  was carried out using a Bioscan 
MeI-Plus (Bioscan Inc., Washington DC, USA) and the methylations occurred in a specially 
designed loop (Autoloop system, Bioscan Inc., Washington DC, USA). The reaction products 
were purified using a semi-preparative HPLC system composed by a HPLC K-501 pump 
(Knauer, Berlin, Germany), a Phenomenex Luna C18(2) 5µ (250x10 mm) reverse-phase HPLC 
column (Phenomenex, Le Pecq Cedex, France), a UV K-200 detector set at 254 nm (Knauer, 
Berlin, Germany), and a suitable radiation detector. On the last step of the synthesis, the desired 
fraction was collected and formulated using a ReFORM-Plus system (Bioscan Inc., Washington 
DC, USA)ReFORM-Plus system. Cold precursors ((R)-[N-Desmethyl]PK11195 and others) were 
purchased from ABX (Advanced Biochemical Compounds, Radeberg, Germany) and all other 
reagents and solvents used in the syntheses were purchased from local suppliers are were of 
Pharm. Eur. grade, when available. 
Quality control (QC) of all radiotracers for PET synthesised during this work, in special 
[11C]PK11195, were performed to verify their purity and safety for injection. For that purpose, an 
Agilent 1200 Series HPLC system (variable wavelength detector) with a Raytest Gabi Star 1207 
radiometric detector (RaytestGmbh, Straubenhardt, Germany) and a Rheodyne (IDEX H&S, 
Wertheim-Mondfeld, Germany) model 7125i syringe-loading sample injector valve with a 20 μl 
loop was used. The chromatographic separation was performed using an analytical reverse-phase  
Agilent Zorbax Eclipse XDB-C18 column (150x4.5 mm; 5μ). A dose calibrator (ISOMED 1010; 
Elimpex-Medizintechnik GesmbH, Mödling, Austria) was used to measure the radioactivity 
concentration and the physical half-life of radioisotope. A gas chromatography (GC) system (GC 
Agilent 6850; RaytestGmbh, Straubenhardt, Germany) was used to monitor residual solvents 
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concentration in final product. The pH was measured using a pH meter (JENWAY 3510 pH; 
Bibby Scientific Limited, Staffordshire, UK). 
 
2.3.2. Automated synthesis module 
2.3.2.1. Methyl iodide production system 
The methyl iodide production system is a commercial synthesiser optimised for the 
production of [11C]CH3I and [
11C]CH3OTf, the workhorses of [
11C]-labelling of PET 
radiopharmaceuticals. The system includes automated procedures for loading of reagents, 
production and cleaning as well as in-process-controls that allow detailed viewing and reporting 
in accordance with modern GMP procedures. At the end of synthesis, the methyl iodide 
production system runs a cleaning procedure which removes all radioactivity and residual 
chemicals. The system is ready to another production. 
This system is composed of multiple hardware modules (Figure 2.2): the main module: the 
solvent delivery module; and the waste delivery module. 
The main module contains electronic and mechanical control circuitry, three temperature 
controlled ovens (molecular sieve, reactor and triflate), electromagnetic valves, a reactor vessel, 
and reagent stations to control the entire process of methyl iodide production. 
The solvent delivery module controls the introduction of cleaning solvents and inert gases 
(nitrogen or helium) into the system. As this module is never exposed to radioactivity, it is 
positioned outside of the shielded cell. This module has 4 solvent bottle positions which are filled 
with ethanol (position 1), acetone (position 2), diethyl ether (position 3) and distilled water 
(position 4). The unit provides solvents and inert gas not only for this system, but also for the 
[11C]-methylation module described on section 2.3.2.2. 
The waste recovery module is the recipient of waste gas and solvents during the synthesis 
and cleaning processes. It contains both a liquid waste reservoir and an ascarite® column to trap 
any radioactive [11C]CO2 that is not trapped in the molecular sieve columns or in the reactor. 
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Figure 2.2 Schematic diagram of the [11C]methyl iodide production system. Solvent delivery module (A) and waste 
recovery module (B) is represented too. A mixture of graphite and silver triflate is placed on a copper column, and 
heated up to 170-180ºC for instantaneous conversion of [11C]CH3I to [11C]CH3OTf ([11C]methyl triflate) (C). This is 
used to convert [11C]CH3I to [11C]CH3OTf, when needed. 
 
2.3.2.2. [11C]methylation system 
Based on the method development by Wison et al. (2000) [67], the [11C]methylation 
labelling system is designed to automate the labelling process by using a captive solvent HPLC 
loop (stainless steel; 2 ml).  
Before the synthesis, the precursor solution is coated on the internal surface of this loop. 
The [11C]-labelling agent carried by the inert gas is then made to flow through the loop where the 
solvent is trapped and made to react with the cold precursor. After the reaction, the mixture is 
introduced into a semi-preparative HPLC column for purification. 
The [11C]methylation system, described on Figure 2.3, is made-up by a commercial HPLC 
injection valve (V1 valve; Rheodyne 7725i; IDEX Health & Science; Wertheim-Mondfeld; 
Germany) that is equipped with a stainless steel loop (2 ml) and an injection port for introducing 
the precursor solution. A 3-way commercial valve (V2 valve; NResearsh; USA) is used to 
introduce the [11C]-labelled gas into the HPLC loop, as well as to introduce the wash solvents on 
beginning of day and on the end of each synthesis. This allows multiple radiosynthesis in one day, 
because an automated wash cycle is performed after each synthesis. There is also a selector valve 
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way (V3) between V2 and the loop which selects the introduction of the [11C]-labelled gas (or 
wash solvents) into the loop, and directs the movement of reacted products from the loop and 
into the HPLC system. 
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Figure 2.3 Schematic diagram of the [11C]methylation system. A: solvent delivery system. B: Waste recovery system. 
 
2.3.2.3. Reformulation system 
The reformulation system is an automated module with the main propose of reformulating 
radiopharmaceuticals from the HPLC mobile phase, into a ready-to-inject dose for clinical use. 
At the front panel, this module has an array of 5 rotary valves adapted to a stopcock cassette 
manifold. A dual pinch valve controls the final product/waste flows. Luer fittings connect the 
hardware cassette tubing to the HPLC input and vacuum and gas pressure ports. 
The disposable reformulation kit, was optimised during this project and is shown in Figure 
2.4. 
 B 
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Figure 2.4 Schematic diagram of the disposable reformulation kit for product formulation used on reformulation 
system. 
 
2.3.2.4. Preparation of system 
On the day of production and before each synthesis, a group of steps are essential to 
prepare the system in order to obtain at the end a product with the quality needed to be ready-to-
inject, with a high radiochemical yield and the highest specific activity possible. 
 
2.3.2.4.1. Preparation of methyl iodide production system 
In the beginning of each day, a cleaning process (‘full system cleaning’ option in ‘System 
preparation’ tab of system software) should be done. The LiAlH4 and HI positions should be 
filled with ethanol (9 ml each). When the system is stopped for a long period of time, it is 
recommended to clean the system the same way, but the vial in the LiAlH4 position filled with 
EtOH (8 ml) and 0.1M HCl (1 ml), and the vial in the HI position with 9 ml of EtOH. All parts 
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of the system are rinsed with ethanol, acetone and diethyl ether using a stream of inert gas 
(nitrogen or helium). When the production of [11C]CH3OTf is needed, the AgOTf column is 
pre-heated to 180ºC. 
Before the beginning of the synthesis, the molecular sieve column is conditioned at 250ºC 
for a minimum of 20 minutes with a stream of inert gas (N2 or He). 
 
2.3.2.4.2. Preparation of the [11C]methylation system 
The [11C]methylation system is cleaned at the beginning of the day and in the end of each 
synthesis. All parts of the module (lines, valves and loop) are rinsed with distilled water and 
acetone, and then purged with a stream of inert gas (nitrogen or helium). Before the injection of 
the precursor solution in the loop, the injection port of HPLC injection valve should be purged. 
For that purpose, the ‘Dry injector valve’ on ‘System preparation’ tab in the system software 
window, should be executed. 
 
2.3.2.4.3. Preparation for reformulation 
After insertion of the kit, a solid phase extraction C18 cartridge (tC18 short) is 
pre-conditioned using 10 ml of ethanol and 10 ml of sterile water, dried and connected to its 
designated position. The fraction collection vial is filled with 20 ml of sterile water. The 3 
reservoirs are filled with sterile water (25 ml), physiological saline (0.9%; 9 ml) and ethanol (1 ml) 
respectively. 
 
2.3.3. Production of [11C]CO2 
All irradiations were performed on a IBA Cyclone 18/9 cyclotron (described on 
section 1.7.2.3) using 18 MeV protons. The [11C]carbon dioxide ([11C]CO2) target was a 50 cm
3 
aluminium target. The target gas used was nitrogen of scientific grade purity (99.9999%) with 
0.5% oxygen. Process gases used were nitrogen, hydrogen and helium of scientific grade 
(99.999%). The gases were purchased from Praxair Portugal Gases, S.A (Maia, Portugal). 
The radioactive starting material, [11C]CO2, was produced by the nuclear reaction 
14N(p,α)11C on the cyclotron target. It was then transferred to a shielded hot-cell (MIP1-1P, 
Comecer S.p.A., Castel Bolognese, Italy) and trapped on a molecular sieve at room temperature. 
This trapped method allows purification of the incoming flow. 
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2.3.4. Production of [11C]CH3I 
Starting from in-target produced [11C]CO2, [
11C]CH3I was synthesised using the chemical 
reaction described by Crouzel et al. in 1987 [69]. 
 
 
Figure 2.5 Reaction scheme for the synthesis of [11C]methyl iodide. 
 
The [11C]CO2 produced on cyclotron is trapped on the molecular sieve (MS) at room 
temperature, that allows a purification of the input stream. After all [11C]CO2 is trapped, the MS is 
heated at 250ºC to release [11C]CO2. Then, it is trapped in a solution of lithium aluminium 
hydride (LiAlH4) in tetrahydrofuran (THF) and reduced to a lithium [
11C]methoxide. The medium 
is then heated to 115-120ºC to evaporate the THF. After the evaporation of the solvent, white 
salt of lithium [11C]methoxide is visible in the reactor. In the following step, hydriodic acid (HI) is 
added to form [11C]methyl iodide ([11C]CH3I) and then distilled off at 115-120ºC temperature in a 
stream of nitrogen or helium.  
The production of [11C]CH3I from [
11C]CO2 can then be summarised in 6 steps:  
 
Table 2.1 Steps for production of [11C]CH3I from [11C]CO2 by the ‘wet method’. 
STEP Description Info 
S1 Production of [11C]CO2 in a cyclotron via the 14N(p,α)11C nuclear reaction by bombarding a target of 
N2+0.2% O2 with high energy protons 
 
S2 Unload the target content to the shielded cell (through the shielded transfer line) and trap it on a 
molecular sieve column at room temperature 
~1.5 min 
S3 Pre-fill the reactor with LiAlH4 ~150 μl 
S4 Release[11C]CO2 from molecular sieves (by increasing the temperature of column; 250ºC) and bubble 
it on the reactor with nitrogen stream 
~1.3 min 
S5 After complete trapping, the solvent (THF) is evaporated; and HI is added to generate [11C]CH3I 
which is distilled by heating the reactor (115ºC) under a continuous nitrogen (or helium) stream 
2.5 min; 
HI: ~350 μl 
S6 [11C]CH3I passes through a dry column (ascarite and P2O5) to remove unreacted [11C]CO2 and dry. 
Then [11C]CH3I is trapped in a loop pre-filled with precursor solution, where methylation reaction 
takes place 
~3min. 
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2.3.4.1. Conversion of [11C]methyl iodide into [11C]methyl triflate 
When [11C]methyl triflate ([11C]CH3OTf or [
11C]MeOTf) is required, it is converted from 
[11C]CH3I by passing it through a column of silver triflate (AgOTf) heated at 175ºC (Figure 2.6). 
 
 
Figure 2.6 Reaction scheme for the convertion of [11C]methyl iodide into [11C]methyl triflate. 
 
2.3.5. Radiosynthesis of (R)-[N-methyl-11C]PK11195 
2.3.5.1. Preparation of precursor solution 
The PK11195 precursor ((R)-[N-Desmethyl]PK11195; 0.25, 0.5 and 1 mg) is dissolved in 
150 µl of DMSO, DMF or MEK and vortexed vigorously for 1 minute. After that, the precursor 
solution is transferred to a vial with a strong base (e.g. KOH; 10, 20 or 30 mg) and vortexed again 
for about 5 minutes. When the base is an aqueous solution (e.g. 8N KOH) or methanol (e.g. 1M 
TBAOH), a small volume of base solution is added to precursor solution and vortexed for a few 
more minutes. The selection of the solvent is important for an efficient trapping of the 
[11C]-methylation agent and their action (or interference) in the methylation reaction. For that 
reason, the solvents must be polar and aprotic as appropriate for a [11C]-methylation reaction by 
nucleophilic substitution. The N-alkylation reaction of (R)-[N-desmethyl]PK11195 precursor 
with [11]CH3I or [
11C]CH3OTf requires the presence of a strong base for deprotonation. 
After preparation, the precursor solution (solvent + (R)-[N-desmethyl]PK11195 + base) is 
slowly injected into the HPLC loop. 
 
2.3.5.2. Labelling reaction 
Once produced, the [11C]-methylation agent ([11C]methyl iodide or [11C]methyl triflate) is 
swept into the HPLC stainless steel loop previously coated with the precursor solution by a 
stream of nitrogen (<15 ml/min) at room temperature.  
After the methylation agent is trapped in loop, the nitrogen flow is stopped and the 
reaction is allowed to proceed for a few minutes (1-5 min). The reaction proceedes (Figure 2.7) 
by the N-methylation of (R)-[N-Desmethyl]PK11195 with a methyl group labelled with 
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carbon-11 via nucleophilic substitution. 
 
 
Figure 2.7 Reaction scheme of the of the (R)-[11C]PK11195 synthesis in a captive solvent loop system. 
 
2.3.5.3. Purification of (R)-[N-methyl-11C]PK11195  
After the reaction on the loop is completed, the mixture is directly injected into a 
semi-preparative HPLC column for purification. The reverse-phase column (Phenomenex, Luna 
C18(2), 5µ, 250x10 mm) is coupled to a ultra-violet detector (UV) at 254 nm (Knauer K-200) and 
a radioactivity detector. The chosen eluent is 0.1 M ammonium formate aqueous 
solution/acetonitrile (40/60) at flow rate of 6 ml/min. The elution time of 
(R)-[N-methyl-11C]PK11195 is about 11.6 minutes with the best conditions listed above. 
 
2.3.6. Product reformulation 
After purification of labelled compounds by HPLC, they must be reformulated into 
ready-to-inject doses for clinical use. This is because the eluent of the HPLC is rarely compatible 
with injection to animals or humans. Reformulation is then needed to remove any organic solvent 
that may be present. For (R)-[11C]PK11195 the method used is solid phase extraction (SPE) [70].  
The product reformulation step is carried out on a reformulation system using a sterile 
disposable kit optimised during this project and suitable reagents, following a sequence of steps 
which are determined by the user selected method. The method uses an SPE (C18) cartridge to 
trap the (R)-[11C]PK11195 from the diluted HPLC mobile phase, rinses any residual organic 
solvents, and releases the compound in a small volume of ethanol followed by dilution with 
NaCl 0.9% and filtration through a sterile 0.22μm filter SLGV033NS (Millex-GV, Millipore). In 
summary, the following steps are involved in the process: 
1. Receiving the product fraction from HPLC purification and dilution in sterile 
water; 
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2. Mixing the product with aqueous phase (sterile water); 
3. Passing the diluted product fraction through the SPE (C18) cartridge, where the 
product (lipophilic) is retained; 
4. Rinsing the SPE cartridge with sufficient sterile water to effectively remove any 
residual organic solvents; 
5. Drying the SPE cartridge with a stream of inert gas (nitrogen); 
6. Eluting the product from SPE cartridge with a small volume of ethanol (<10 % of 
total final product volume); 
7. Diluting the product in the final product vial (FPV) with buffered saline to have the 
correct osmolarity and acceptable ethanol concentration; 
8. During steps 6. and 7. the solutions passes through an sterile 0.22 μm filter to FPV; 
9. After removal of the vial with the (R)-[11C]PK11195 solution, a bubble point test is 
performed on the sterilization filter to ensure the integrity of the membrane. 
At the end of the reformulation process, the product is prepared for quality control. 
 
2.3.7. Quality control 
Authentic samples of the compound and precursor of (R)-[11C]PK11195 were obtained 
commercially from ABX (Advanced Biochemical Compounds, Radeberg, Germany) and were 
used without further purification. All other chemicals were of reagent or HPLC grade unless 
otherwise stated. The standard solutions were prepared in acetonitrile and water and then further 
diluted with water to the desired concentrations. 
Chemical and radiochemical impurities were detected and quantified using analytical 
radio-HPLC. Acetonitrile and 0.1 M ammonium formate (75/25; v/v) were used as mobile phase 
with a flow rate of 2 ml/min on a reverse-phase C18 (Agilent Zorbax Eclipse XDB-C18; 
150x4.5 mm; 5μ) analytical column. The whole HPLC analysis was completed within 10 min, the 
retention time of the precursor ((R)-[N-methyl-11C]PK11195) was 2.5-3.1 min and the product 
[11C]PK11195 was eluted with a retention time of 1.8-2.4 minutes. The chemical identity of 
[11C]PK11195 was determined by co-injection of the unlabelled reference compound, 
(R)-[N-methyl-12C]PK11195 (sample chromatogram is shown in Figure 2.8). For calculation of 
radiochemical purity, the portion of [11C]PK11195 in relation to total radioactivity was 
determined (threshold ≥95%). Residual solvents were analysed by gas chromatography (GC 
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Agilent 6850; RaytestGmbh, Straubenhardt, Germany). The radiochemical purity was assessed by 
measurement of the physical half-life on dose calibrator (ISOMED 1010; Elimpex-
Medizintechnik GesmbH, Mödling, Austria). pH was measured on a pH meter (JENWAY 3510 
pH; Bibby Scientific Limited, Staffordshire, UK). 
 
 
Figure 2.8 Analytical UV HPLC trace for co-injection of (R)-[N-methyl-12C]PK11195 standard solution and 
(R)-[N-desmethyl]PK11195 precursor solution. 
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Results 
A full [11C]PK11195 synthesis process was optimised for routine in about 35 minutes from 
EOB. 
 
Figure 3.1 Radiosynthesis progress of (R)-[N-methyl-11C]PK11195 from EOB to EOS. 
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3.1. Production of [11C]methyl iodide: initial optimisations 
The main parameters for [11C]methyl iodide production were optimised to achieve the 
highest possible yields and insure reliability and reproducibility. The optimal settings are showed 
on Table 3.1. 
 
Table 3.1 Production conditions for [11C]CH3I. 
Setting Value 
Timer for LaH dispensing (milliseconds) 150 
Timer for HI dispensing (milliseconds) 700 
CO2 trapping time (mm:ss) 01:30 
CO2 release time (mm:ss) 01:20 
THF evaporation time (mm:ss) 02:30 
CH3I distillation time (mm:ss) 03:00 
Molecular sieve oven temperature (ºC) 250 
Reactor oven temperature (ºC) 115 
Methyl triflate oven temperature (ºC) 175 
 
With these settings, [11C]CH3I production is completed in 11.39±0.76 minutes (from EOB; 
Figure 3.2). The radiochemical yield and specific activity of [11C]CH3I produced were 70.79±7.6% 
(non-decay corrected) and 499.32±72.77 mCi/μmol (18.47±2.69 GBq/μmol), respectively. 
 
 
Figure 3.2 Diagram of in-process controls during [11C]CH3I production.. 
 
The production of [11C]methyl iodide is a critical step for specific activity optimisation. The 
SA of [11C]CH3I obtained via ‘wet method’ is largely affected by sources of stable CO2. An 
evaluation and identification of the main sources of 12C involved in the [11C]CH3I production 
using this method is the subject of the following section. 
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3.1.1. Specific activity optimisation 
3.1.1.1. Evaluation of molecular sieve pre-conditioning influence on amount of [12C]CH3I 
generated 
A molecular sieve is a material that can adsorb carbon dioxide at low temperature (room 
temperatures), and released it when heated to high temperatures (250ºC). In our tests we used 
two different scenarios: 1) synthesis without pre-conditioning the molecular sieves before; and 2) 
synthesis with pre-conditioning molecular sieves at 250ºC during 20 minutes just before the 
beginning of synthesis. Both tests were done without unloading the cyclotron target to the 
molecular sieve. 
The amount of CH3I formed in two scenarios was measured by HPLC. The results showed 
that without pre-conditioning of MS, the production of stable methyl iodide increases 315%. The 
production of CH3I under scenario 1 was 530.56±340.88 nmol and 168.10±36.51 nmol under 
scenario 2 (Figure 3.3). 
 
 
Figure 3.3 Amount of ‘cold’ CH3I formed without pre-conditioning of molecular sieves before synthesis (A) and 
with pre-conditioning just before the synthesis (B). 
 
3.1.1.2. Sources of 12C from the inert gas purity 
Aiming to investigate the influence of potential impurities in the gas supply in the final 
amount of CH3I produced, we developed an in-house filter by preparing a column with ascarite 
and phosphorus pentoxide. The results show that the final amount of CH3I was 
168.10±36.51 nmol without filtration and 59.54±7.20 nmol with filtration (Figure 3.4). 
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Figure 3.4 Amount of ‘cold’ CH3I formed without filtration of inert gas supplier of methyl iodide system and with 
filtration. 
 
3.1.1.3. Sources of 12C involved on [11C]CH3I production from reagents, materials, and 
load-unload of the target 
Three different tests were performed to evaluate the source of 12C from the gases, materials 
and reagents used on methyl iodide production process. Results were obtained from 3 scenarios 
(Figure 3.5A): 
Scenario Sc1: Synthesis was carried out by executing step S3 and S5 (Table 2.1) of the general 
procedure. Transference of the target material and the CO2 release from the molecular sieves 
were skipped. 
Scenario Sc2: Synthesis was carried out by executing step S3, S4 and S5 (Table 2.1) of the 
general procedure. Transference of the target material was skipped. 
Scenario Sc3: Synthesis was carried out by executing step S2, S3, S4 and S5 (Table 2.1) of the 
general procedure. 
The nitrogen input was filtered on all scenarios. 
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Figure 3.5 Amount of [12C]CH3I (in nmol) generated under scenarios Sc1, Sc2 and Sc3 described above (A). The 
influence of [12C]CO2 source by LiAlH4 (Sc1), release of CO2 from MS (Sc2) and the load-unload of the target (Sc3) 
was shown on graph of the right (B). 
 
The individual contribution of each source of 12C involved on the CH3I production is 
shown on Figure 3.5B. Under scenario Sc1 47.938±0.841 nmol of stable methyl iodide were 
generated. This is expected to come from the CO2 on the LiAlH4 solution, absorbed from the 
atmosphere, or from methanol formed from THF remaining on LiAlH4 after evaporation. Under 
scenario Sc2 8.190±5.262 nmol of stable methyl iodide were generated, by the contribution of 
CO2 adsorbed to the molecular sieves even after conditioning. Finally under scenario Sc3 
69.115±22.597 nmol of stable methyl iodide were generated, by the contribution of CO2 from 
load-unload target processes, such as from CO2 adsorbed on the target chamber, in the 
stainless-steel tubing that connect target to the synthesis module, or from its presence in the 
target gas. 
 
3.1.1.4. Sources of 12C involved on [11C]CH3I production: from effect of bombarding time 
Finally, we tested the contribution of bombarding time for the final amount of stable 
methyl iodide. As showed on Figure 3.6, the longer the bombarding time, the higher stable 
methyl iodide produced. 
 
A B 
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Figure 3.6 Effect of the bombarding time on the final amount of [12C]CH3I (in nmol). 
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3.2. Captive solvent loop methylation: initial optimisations 
3.2.1. Solvents and bases chosen 
The right choice of the polar aprotic solvent for the synthesis is important not only because 
of its effect on the nucleophilic substitution [11C]-methylation reaction on a loop, but also 
because of the the trapping efficiency in [11C]-methylation precursor on the loop. For that 
purpose, we compared the trapping efficacy of three different solvents. 
DMF (dimethylformamide) and DMSO (dimethyl sulfoxide), both anhydrous, were used on the 
synthesis with [11C]methyl iodide. MEK (methyl ethyl ketone) and DMSO were tested too, in 
their trapping efficacy, when [11C]methyl triflate was used as a methylation agent. These solvents 
were selected according to their ability to dissolve the (R)-[N-desmethyl]PK11195 precursor. In 
each test, 0.5 mg of precursor was dissolved in 100 µl of solvent, and then injected into captive 
solvent loop. The experimental results of precursor solvent efficiency on trapping are shown on 
Figure 3.7, and the trap efficacy of DMSO (56.09% with [11C]CH3OTf and 93.83±3.90% with 
[11C]CH3I) is a good indication that it is close to ideal as a precursor solvent. 
 
 
Figure 3.7 Influence of precursor solvent (MEK, DMSO and DMF) on the trapping efficacy of [11C]CH3I and 
[11C]CH3OTf (*) on the captive solvent loop. 
 
R)-[N-methyl-11C]PK11195 is labelled with 11C by an N-alkylation reaction, that is aided by 
a strong base for deprotonation. Two different strong bases were used with various 
concentration, to evaluate their efficacy on N-deprotonation. Summary of the results are shown 
on Table 3.2. 
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Table 3.2 Summary of the results of influence of different solvents and bases in the synthesis of (R)-[N-methyl-
11C]PK11195. 
Solvent Base [11C]-methylation 
agent 
Average 
trapping 
efficiency of 
[11C]CH3I (%) 
(mean±σ) 
Average % of 
(R)-[N-methyl-11C]PK
11195 RCY (DC)  
(mean±σ) 
(R)-[N-methyl-11C]PK
11195 at EOS (mCi) 
(mean±σ) 
n 
MEK TBAOHa [11C]CH3OTf 32.48±9.40 5.11±2.56 6.90±1.41 3 
DMSO KOHb [11C]CH3OTf 56.09 2.14 1.90 1 
DMF TBAOHa [11C]CH3I 40.87 0 0 1 
DMF  KOHb [11C]CH3I 90.09 0.83 2.13 1 
DMSO KOHb [11C]CH3I 93.83±3.90 31.58±9.97 107.85±52.13 10 
DMSO KOHc [11C]CH3I 62.74±18.06 4.41±2.78 5.45±2.73 3 
a TBAOH (1M) in methanol (TBAOH: tetrabutylammonium hydroxide); 10 µl 
b KOH (potassium hydroxide); precursor solution was saturated with 30 mg of KOH 
c KOH (8N) aqueous solution; 2 µl 
 
3.2.2. Precursor concentration: influence on RCY 
The amount of precursor (concentration) in the synthesis of [11C]PK11195 is an important 
issue not only for the radiochemical yield (RCY), but also in the ratio [11C]PK11195/[11C]CH3I. 
The total activity amount of [11C]PK11195 at the EOS was evaluated too, and correlated with 
precursor concentration. 
The synthesis conditions were: the desired amount of precursor was dissolved in 100 µl of 
DMSO, and saturated with 30 mg of KOH; and reacted 5 min on loop. All loop preparation 
processes were made just before the injection of the precursor solution. The experimental results 
are summarised on Table 3.3. 
 
Table 3.3 Influence of precursor concentration in the synthesis of [11C]PK11195. 
Precursor 
concentratio
n 
(mg/100µl) 
Average amount of 
[11C]CH3I activity 
produced (mCi) 
(mean±σ) 
Average amount of 
[11C]PK11195 
activity produced 
(mCi) (mean±σ) 
Average % of 
[11C]PK11195 RCY 
(n.d.c.) (mean±σ) 
[11C]PK11195/[11C]CH3
I ratio (mean±σ) 
n 
0.25 37.82±31.82 13.70±9.70 6.6±1.4 0.5±0.17 
4 
4 
0.5 73.92±56.97 96.32±13.31 17.8±5.2 2.6±2.05 
1 39.40±16.81 131.73±67.99 20.9±4.0 3.2±0.52 
 
Thus, increasing the amount of precursor, will increase not only the RCY of [11C]PK11195 
but also the total amount of activity at EOS (Figure 3.8). 
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Figure 3.8 Influence of precursor ((R)-[N-desmethyl]PK11195) concentration in radiochemical yield (RCY) and in 
the ratio [11C]PK11195/[11C]CH3I (left) and total amount of radioactivity of both at EOS affected by precursor 
concentration (right). (n=4). 
 
3.2.3. Reaction time 
We also evaluated the influence of reaction time on the synthesis of [11C]PK11195, with 
0.5 mg of precursor dissolved in 100 µl of DMSO, and saturated with 30 mg of KOH. All loop 
preparation processes were made just before the injection of the precursor solution. The results 
show that increasing the reaction time of 1 min to 3 min, and then to 5 minutes, results in an 
increase of RCY of the [11C]PK11195 product. Productions of [11C]PK11195 were 58.4, 118.3 
and 234.3 mCi with 1, 3 and 5 minutes of reaction, respectively (Figure 3.9). 
 
 
Figure 3.9 Effect of reaction time in [11C]PK11195 production. Radiochemical yields (left) and total activity of 
[11C]PK11195 at the end of synthesis (mCi; right); (n=1). 
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3.3. Purification and formulation of (R)-[11C]PK11195 
After the reaction in the loop, the crude mixture is injected into a semi-preparative HPLC 
column for purification.  
The retention times were 10.8-12.5 minutes for (R)-[N-methyl-11C]PK11195 and 15.8-17.5 
minutes for (R)-[N-desmethyl]PK11195 on the semi-preparative HPLC (Figure 3.10). 
 
 
Figure 3.10 Semi-preparative HPLC separation of (R)-[N-methyl-11C]PK11195 (Rt: 11.7 min). HPLC conditions–
column: Phenomenex Luna C18(2) 5µ (250x10 mm) reverse phase column; mobile phase: 0.1N aqueous solution and 
acetonitrile (40:60); and flow rate: 5 ml/min. (Decay corrected and background removed). 
 
SPE purification resulted in a recovery of >95 % using 1 ml of ethanol followed by 9 ml of 
physiological saline solution (NaCl 0.9%) for the elution of [11C]PK11195 . 
 
 
Figure 3.11 Formulation of [11C]PK11195 by solid phase extraction on the reformulation system. 
 
(R)-[11C]PK11195 
(R)-[N-desmethyl]PK11195 
C
o
ll
ec
te
d
 f
ra
ct
io
n
 
Pull from 
SPE 
Elution 
with EtOH 
Collect and 
dilution in 
intermediate 
vial 
Dry 
SPE 
Wash SPE 
with sterile 
water 
Elution with 
NaCl 0.9% 
Enf of 
formulation 
Results 57 
 
3.3.1.1.1. Product filtration 
A measure of the sterilization filter after reformulation, showed that a large amount of 
activity was trapped on the first filter used (Millex-GS; 0.22µm). To confirm this result and make 
an evaluation of the problem, several filtration tests of the ‘cold’ product ((R)-PK11195) were 
made. Three different types of filter were used in these experiments (Figure 3.12). 
The (R)-PK11195 standard was solubilised in a mixture of saline and ethanol (solution of 
saline with 10 % of ethanol). From the concentration of the standard solution before injection 
and the measure by HPLC after injection, it was possible to evaluate the ratio of retention of the 
different filters. 
Test 1 (GS): The standard solution of (R)-PK11195 was filtered with a Millex-GS Millipore 
(0.22µm) filter (mixed cellulose esters) and the filtrate was then subjected to injection into 
analytical HPLC. 
Test 2 (GV): The standard solution of (R)-PK11195 was filtered with a Millex-GV 
Millipore (0.22µm) filter (polyvinylidene difluoride or PVDF) and the filtrate was then subjected 
to injection into analytical HPLC. 
Test 3 (minisart): The standard solution of (R)-PK11195 was filtered with a Minisart® 
Sartorius Stedim (0.2µm) filter and the filtrate was then subjected to injection into analytical 
HPLC. 
 
 
Figure 3.12 Filtration testes of (R)-PK11195 with 0.22µm sterile filters using a solution of saline at 10% of ethanol. 
(n=3). 
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The results show that the Millex-GV column retains less product then the Millex-GS and 
the Minisart. Using a saline solution of (R)-PK11195 with 10% EtOH, we obtained a filtered 
solution with a concentration of 89.02±6.92 % of the initial value. 
Hot tests with the labelled compound ((R)-[N-methyl-11C]PK11195) confirmed this result 
and with a volume of 1 ml of EtOH, the labelled product was quantitatively recovered in the final 
vial. 
 
3.4. Routine radiolabelling of (R)-[N-methyl-11C]PK11195 
The conditions for routine radiolabelling of [11C]PK11195 involve an irradiation time of 
about 30 minutes on the cyclotron with an integrated current of about 12.8 μAh. During the 
irradiation time, the molecular sieves (MeI-Plus) are pre-conditioned (heating at 250ºC for about 
20 minutes). 
The reaction conditions are: 0.5 mg of precursor (N-desmethyl-PK11195) dissolved in 
100 μl of DMSO and then saturated with 30 mg of KOH; reaction in the loop for 5 minutes with 
[11C]CH3I. DMSO as a solvent, KOH as the base, and the [
11C]CH3I as methylation precursor 
offered the best productions of [11C]PK11195 (141.29±57.15 mCi at end of reformulation). 
[11C]PK11195 is easily separated from precursor, solvents and other products by the semi-
preparative HPLC. 
Radiochemical purity exceeded 99% as determined by radio-HPLC. No contamination with 
N-desmethyl-PK11195 precursor was observed (Figure 3.13). Residual solvents as determinate by 
GC were found to be 672.09 mg/10 ml ethanol and 3.28 mg/10 ml acetonitrile. pH was 6.19. 
The specific activity of the final product ([11C]PK11195) was between 15-25 GBq/μmol and the 
radiochemical of about 10-16% (non-decay corrected). 
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Figure 3.13 Analytical HPLC traces for a final (R)-[N-methyl-11C]PK11195 product sample (Rt: 2.07 min). HPLC 
conditions: Agilent Zorbax Eclipse XDB-C18 (150x4.5 mm; 5μ) reverse phase column; mobile phase: water and 
acetonitrile (75:25); flow rate: 2 ml/min. 
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Discussion 
The radioligand [11C]PK1195 was synthesised for the first time by the French company 
Pharmuka in 1984 [38]. The compound is a non-benzodiazepine high-affinity selective TSPO 
ligand and was labelled with carbon-11 as a PET imaging probe for neuroinflammation. Despite 
the limitations of carbon-11, related to its short half-life, PK11195 has remained the most widely 
used molecule for in vivo PET studies of TSPO.  
The aim of this work was to optimise the synthesis, purification and reformulation of 
[11C]PK11195 by the captive solvent method using a series of modules available at ICNAS for the 
production of methyl iodide, methylation in a captive solvent loop and reformulation by solid 
phase extraction. Automated radiosynthesis of compounds is common in PET production 
centres as it diminishes considerably doses on staff, provides a reliable and reproducible platform 
for production and facilitates record keeping and GMP compliance. A fundamental step of the 
process is the initial setup and optimisation of a synthesis that, considering there each installation 
is unique in its nature, requires substantial work in adapting production methods from the 
literature to the specific setup of each site. 
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4.1. Automation of [11C]methyl iodide production 
The first step of this work was dedicated to the [11C]CH3I production optimisation 
parameters. The goal was to establish a rapid and reliable way to produce [11C]CH3I with high 
radiochemical yields and with high specific activities. SA is a critical paramenter for a 
radiopharmaceutical and corresponds to the amount of radioactivity per unit mass of the 
compound. Thus, a low SA represents a higher mass of cold compound being injected with 
detrimental effects on image quality and possible pharmacotoxic effects on the subject. 
In the production of methyl iodide at ICNAS, the labelled carbon-11 source comes from 
carbon dioxide labelled with 11C produced on the cyclotron. This [11C]CO2 is then used to 
produce [11C]CH3I. Any possible source of stable carbon (in form of CO2) present in lines of 
module, reagents, gas impurities and material of the target chamber, will also react with LiAlH4 
and reduced to stable methanol salt. After evaporation of THF, and with addition of HI, stable 
methyl iodide is formed by distillation, which will decrease the specific activity of the final 
product. Therefore, the methyl iodide production system has to be optimised to potentiate the 
use of 11C and to reduce, as much as possible, any potential sources of stable carbon (12C). 
The optimised parameters, as showed on Table 3.1, resulted in a production of [11C]CH3I 
in about 10.57 minutes (from EOB) with radiochemical yields of 70.79±7.6% (NDC) and with 
very high reliability. In the end, more than 70% of the total activity received from the cyclotron 
(EOB) was converted to gaseous distilled [11C]methyl iodide. 
 
4.1.1. Specific Activity 
When the aim of identifying potential causes for the low specific activities associated with 
the production of methyl iodide by the so-called ‘wet’ method, we planned a series of 
experiments in order to assess the contribution of each individual element to the final amount of 
unlabelled carbon. For that purpose, we investigates the contribution to the SA of the synthesis 
module components (molecular sieves, pre-conditioning, volume of reagents and gas purity), the 
target, and the irradiation time. 
When molecular sieves aren’t pre-conditioned, values of 530.56±340.88 nmol of stable 
methyl iodide were found, and 168.10±36.51 nmol was found when pre-conditioning of 
molecular sieves been done before the start of synthesis (Figure 3.3). So, pre-conditioning of 
molecular sieves at 250ºC for 20 minutes should always be performed, to release any absorbed 
CO2 before the beginning of a synthesis run. 
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Next, were investigated the contribution of inert gas purity (nitrogen) in the final amount 
of stable methyl iodide. When N2 was used without any purification, values of 
168.10±36.51 nmol of stable methyl iodide were found. With the installation of an 
Ascarite®/P2O5 column at the entrance of module, only 59.54±7.20 nmol were found (Figure 
3.4). Furthermore, we noticed that when drying the N2 with P2O5 the THF evaporation is more 
efficiently. We then concluded that a purification (filtration) of gases used in methyl iodide 
production is essential, and proceed to use then at every synthesis.  
In a third step, the contribution from the reagents, the molecular sieves, the target chamber 
and the transfer line were investigated. The individual contribution of these factors was: 
47.938±0.841 nmol of stable methyl iodide was found due to the contribution of stable CO2 
from the CO2 adsorbed on LiAlH4 solution, from the atmosphere due to lack or tightness of the 
synthesis module, or from methanol formed from THF remaining on LiAlH4 after evaporation; 
8.190±5.262 nmol of stable methyl iodide was found due to the contribution of stable CO2 
adsorbed on molecular sieves; and 69.115±22.597 nmol of stable methyl iodide were found due 
to the contribution of CO2 from load-unload target processes, such as from CO2 adsorbed on the 
target chamber, in the stainless-steel tubing that connect target to the synthesis module, or from 
presence in the target gas. Considering these results, it is clear that a reduction of LiAlH4 loaded 
volume and a purification of the nitrogen/oxygen mixture leads to a substantial increase of the 
specific activity. 
Finally, were investigated the formation of stable CO2 during the bombarding processes. 
As it can be seen in Figure 3.6, methyl iodide production with 1 μAh of bombardment led to the 
production of 348.48±121.10 nmol of stable CH3I. When bombarding time was increased 
(integrated currents of 2, 5 and 10 μAh), 428.54±27.36, 447±16.16 and 570.72±125.82 nmol of 
stable methyl iodide were found. These results show that the first minutes of bombardment 
contribute to a great amount of stable carbon dioxide formed during the target irradiation 
(224.24±143.36 nmol were found due to integrated of 1uAh). The non-linear results of stable 
methyl iodide formation with increasing of bombarding time, suggests that the main source of 
non-radioactive (stable) carbon dioxide during the full synthesis of [11C]CH3I is due to the 
presence of carrier carbon contamination in the target content and that the material is formed 
primarily during the first minutes of bombardment. This formation of stable CO2 (combustion) is 
greater and faster on the beginning of the bombardment because of the higher concentration of 
carrier carbon, which decreases as the combustion takes place. 
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Considering the obtained results, was decided to implement a set of procedures in order to 
improve the radiochemical yield of the methyl iodide production and improved the specific 
activity of PK11195 labelled with carbon-11 via the ‘wet’ method. These procedures are: 
1. Definitive modification:  
a. Installation of a trap in nitrogen gas supply entry, for remove the 
introduction of stable carbon in lines; 
b. Reduction of the volume of LiAlH4 loaded. 
2. Preparation of the synthesis module: 
a. Cleaning the system (EtOH, acetone and diethyl eter) and drying with 
nitrogen; 
b. Loading the reagents into module; 
c. Loading, bombarding the target (integrated current: 1µAh) and unloading to 
module, by running a simple methyl iodide production method; maintaining 
the target pressurised at 20 bar; 
d. The system is cleaned automatically; 
e. Pre-conditioning (at 250ºC for 30 minutes) the molecular sieves column to 
eliminate residual CO2; 
f. Maintaining the system pressurised. 
3. Periodical check-ups to system to follow possible leaks on the system lines. 
 
4.1.2. Synthesis module: routine maintenance  
Following the experience acquired with the synthesis module, a set of procedures was 
established to maintain the high reliability of the production. This is summarised below. 
1. Every day before the first synthesis, an inspection of the general conditions of the 
module should be performed (look for valves leaks; test operation of valves, ovens 
and reactor oven elevator); 
2. In the end of the day, after the last production, the module should always be 
cleaned to avoid residues to build up and cause malfunctioning in subsequent 
productions; 
3. Reagents needles should be changed every working day; 
4. The molecular sieves should be replaced whenever there is an insufficient trapping 
of [11C]CO2 gas. 
Discussion 65 
 
5. Drying column (with ascarite and P2O5) between methyl iodide production system 
and and loop should be replaced at the beginning of each production day. 
6. Inert gas should be purified to improve radiochemical yields and specific activity. 
 
4.2. Radiolabelling (R)-[11C]PK11195 on a captive solvent loop 
The production of radiopharmaceuticals with short-live positron emitters relies heavily on 
the use of semi-preparative HPLC systems for purification of the final reaction mixture. It is 
therefore of great convenience that we use the sample HPLC loop for the labelling reaction. This 
is the basis of the captive solvent loop developed by Wilson et al. work [67]. In this system, the 
methylation agent is trapped and made to react with the precursor solution pre-loaded onto the 
loop. Using this method, a large variety of PET radiopharmaceuticals labelled with carbon-11 can 
be produced. In this work we demonstrated that, with the right choice of solvent, base, time of 
reaction and eluents for HPLC purification, labelling of [11C]PK11195 with this method is 
possible with good quality and reliability. 
 
4.2.1. Initial optimisation 
A critical parameter on a nucleophilic substitution reaction is the selection of an adequate 
polar aprotic solvent. We evaluated different solvents in the trapping efficiency of [11C]CH3I or 
[11C]CH3OTf after establishing their ability to dissolve the (R)-[N-desmethyl]PK11195 precursor. 
The experimental results are shown on Figure 3.7, and DMSO proved to be the best choice 
on trapping efficacy (56.09% of [11C]CH3OTf and 93.83±3.90% of [
11C]CH3I). A strong base is 
also needed on the precursor solution for deprotonation (R)-[N-desmethyl]PK11195 for 
[11C]-methylation reaction by an N-alkylation. According to the results showed on Table 3.2., 
radiochemical yields were higher when the precursor solution was saturated with 30 mg of KOH. 
The amount of precursor injected into the loop should be sufficient to produce good 
radiochemical yields. However, it should not be excessive to ensure a good separation from 
[11C]PK11195 by reverse-phase HPLC, and to help maintain the cost of the synthesis low. As it 
can be seen by the results, with 1 mg of precursor, we obtained radiochemical yields of about 
20.9±4.0% (non-decay corrected), whereas with 0.5 mg were obtained RCY of 17.8±5.2% 
(NDC). Although the ratio between labelled [11C]PK11195 and unlabelled [11C]CH3I is higher 
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with 1 mg of precursor, the radiochemical yields suggest that 0.5 mg of precursor is enough to 
obtain the desired amount of labelled [11C]PK11195 in the end of synthesis.  
Finally, the reaction time of 5 minutes in the loop with precursor dissolved on 100μl of 
DMSO and saturated with 30 mg of precursor, provided the best production of [11C]PK11195 
with RCY about 43.13% and activity on EOS about 234.3 mCi. 
 
4.2.2. Purification and reformulation of (R)-[11C]PK11195 
Purification of (R)-[N-methyl-11C]PK11195 was performed successfully by reverse-phase 
HPLC C18 column (Phenomenex Luna C18(2), 5µ, 250x10 mm). It is an octadecyl carbon chain 
(C18) where compounds are separated based on their hydrophobic character. 
The mobile phase chosen was a 0.1N ammonium formate aqueous solution / acetonitrile 
(40:60) with a flow of 5 ml/min. With this optimised parameters, [11C]PK11195, the precursor 
and other reaction products were properly separated with retention times of 10.8-12.5 minutes 
for (R)-[N-methyl-11C]PK11195 and 15.8-17.5 minutes for (R)-[N-desmethyl]PK11195 (Figure 
3.10).  
The final step of the synthesis process is the reformulation of [11C]PK11195 collected 
fraction on a ready-to-inject dose by SPE.  A C18 column was used with an optimised 
reformulation disposable kit. SPE purification resulted in a recovery of >95 % using 1 ml of 
ethanol followed by 9 ml of physiological saline solution (NaCl 0.9%) for the elution of 
[11C]PK11195. Using the Millex-GV filter and a volume of 1 ml of EtOH, there were no 
problems of filtration and the labelled compound ((R)-[N-methyl-11C]PK11195) was 
quantitatively recovered in the final vial. 
 
4.3. Routine synthesis, purification and reformulation of 
(R)-[N-methyl-11C]PK11195 
Production of [11C]methyl iodide results showed good reproducibility and that the amount 
of radioactivity produced after the 10µAh irradiations (1173.9±85.5 mCi), was sufficient for the 
radiosynthesis of the PK11195 in sufficient quantity and quality for human use. Good distillation 
yields were obtained (84.12±12.03 %) and sufficient for the N-methylation of the desmethyl-
PK11195 precursor. For the labelling reaction, 0.5 mg of precursor (N-desmethyl-PK11195) was 
dissolved in 100 μl of DMSO and then saturated it with 30 mg of KOH, and injected into the 
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loop and made to react for 5 minutes with [11C]CH3I. 141.29±57.15 mCi of [
11C]PK11195 at 
EOS were obtained and were easily separated from precursor, solvents and other products by the 
semi-preparative HPLC. 
Radiochemical purity exceeded 99% as determined by radio-HPLC. No contamination with 
N-desmethyl-PK11195 precursor was observed (Figure 3.13). Residual solvents as determinate by 
GC were found to be 672.09 mg/10 ml ethanol and 3.28 mg/10 ml acetonitrile. pH was 6.19. 
The specific activity of the final product ([11C]PK11195) was between 15-25 GBq/μmol and the 
radiochemical of about 10-16% (non-decay corrected). All parameters are within specification for 
human use. 
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Conclusion 
The present work aimed to optimise the synthesis, purification and reformulation of 
(R)-[11C]PK11195 using the captive solvent method and make its available on a ready-to-inject 
sterile saline solution for PET imaging studies of neuroinflammation. PK11195 is a lipid soluble 
isoquinoline carboxamide that, when labelled with carbon-11 ((R)-[11C]PK11195), can be used as 
an in vivo molecular imaging probe for the TSPO receptor. This 18 kDa translocator protein is 
overexpressed when microglia is activated, a main feature of neuroinflammation. 
Improved and efficient synthesis of (R)-[N-methyl-11C]PK11195 on an automated synthesis 
system was optimised for routine production with excellent radiochemical yields and good 
specific activities. Initially, the production of [11C]methyl iodide was improved by establishing the 
optimal production parameters. Possible sources of stable CO2 were investigated in order to 
obtain the best possible specific activity. Secondly, solvents, bases and times of reaction were 
optimised for the best radiochemical yield using the captive solvent loop. Finally, reaction 
products were purified by HPLC and formulated by SPE on a ready-to-inject non-pyrogenic 
saline solution. 
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Quality control tests were performed to ensure the good quality of product. Activity 
obtained was 149.71±50.25 mCi of (R)-[11C]PK11195 at EOS with specific activities between 15-
25 GBq/μmol on a short overall synthesis time. 
The approach that we have developed allows the reliable and reproducible preparation 
[11C]-radiopharmaceuticals such as (R)-[11C]PK11195 several times a day, with activity and quality 
suitable for human studies. The optimizations made are applicable to most methylation syntheses 
by this method and are already being used at the lab for the development of the next generation 
of 11C-based radiotracers.  
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Future perspectives 
 
Although the results of this work proved that we can produce (R)-[11C]PK11195 with 
specific activity suitable for human studies, other tracers, mainly for targets that are poorly 
expressed in tbe region of interest or are destined for small animal research, require even higher 
levels of specific activity.  
For that purpose, there is an interesting challenge in the short term, that is the production 
of [11C]CH3I from the in-target production of [
11C]methane ([11C]CH4). This method of [
11C]CH3I 
production, also referred to as the ‘gas phase’, exploits the conversion of [11C]CH4 into [
11C]CH3I 
by free radical iodination with iodine vapour at high temperatures (700-750ºC) in the gas 
phase [71]. The production of [11C]CH3I via the ‘gas phase’ method offers several advantages 
over the ‘wet’ method route. Firstly, it avoids the problem of stable CO2 present on LiAlH4, 
hence leading to a high specific activity. Likewise problems of low specific activities associated to 
stable CO2 present on gases, target chambers, and others source, are skipped. Secondly, 
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avoidance of hydriodic acid prevents valves and tubing from deterioration. With implementation 
of ‘gas phase’ method on routine production of [11C]-radiopharmaceuticals we expect a significant 
increasing of specific activities. 
Other desired and promising demand is the introduction of microreactors in 
radiochemistry for enable reactions performed more rapidly, efficiently, and selectivity. This type 
of ‘microchemistry’ allows reducing the amount of reagents used in the reactions. And with some 
optimisation in time and temperature, allows us to perform reactions that are very difficult to 
control in a reactor, or loop. 
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